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ABSTRACT 
 
Glucocorticoids enhance the maturation of premature lung. Antenatal glucocorticoids reduce 
the risk of respiratory distress syndrome and neonatal death in preterm infants, and postnatal 
dexamethasone (DEX) facilitates weaning from the ventilator. However, these drugs may 
disturb the growth and development of lung and brain. To evaluate the long-term effects of 
antenatal or postnatal DEX treatment, we studied 49 children aged 7.3-9.2 years, born very 
prematurely at 24-30 gestational weeks and with 600-1575 g of birth weight in 1989-1991, 
who had participated in randomized placebo-controlled trials of neonatal DEX therapy 
administered to ventilated infants at high risk for bronchopulmonary dysplasia (BPD) (n=16) 
or/and antenatal DEX therapy in conjunction with exogenous surfactant (n=35). 
Cardiorespiratory morbidity, neurological outcome and the family history of smoking or 
atopy were evaluated using hospital records and questionnaires. Physical examination, skin 
prick tests, impulse oscillometry, flow-volume spirometry, pulmonary diffusing capacity test 
and whole-body plethysmography were carried out, and the oscillometric method was 
compared with the conventional lung function methods. Lung inflammation was studied by 
exhaled nitric oxide (eNO) measurement and cardiac outcome by chest X-ray, 
electrocardiogram and echocardiography. The control group consisted of 18 non-atopic 
children born at term and tested for lung function.  
Antenatal or neonatal DEX had no negative effect on cardiopulmonary outcome. On the 
contrary, the children born after antenatal placebo showed greater bronchodilator 
responsiveness (∆FEV1) than those born after antenatal DEX.  
Severe or moderate disability was common in our prematurely born children (29%). 
Neurosensory outcome did not differ between the neonatal DEX and placebo groups. 
However, antenatal DEX treatment associated with a higher rate of normal school attendance 
and less severe or moderate disability. 
The children born prematurely, particularly boys, were shorter for age than the controls. 
The BPD children weighed less adjusted for height than the non-BPD children. Antenatal or 
postnatal DEX treatment had no significant effect on weight or height. 
Half of the children born prematurely reported frequent respiratory symptoms during the 
preceding year, with no association with BPD or either DEX treatment. Poorer exercise 
tolerance and more common use of inhaled medication were reported in the BPD group. 
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Atopy was rare in the children with BPD. Atopy associated with significantly increased 
eNO concentrations. In non-atopic children, eNO levels correlated neither with the values of 
lung function measurements nor with BPD. Thus, eNO was not an inflammatory marker of 
BPD at school age, but it may be valuable in studying atopic asthma even in children born 
prematurely. 
Airway obstruction, bronchial hyperreactivity and decreased gas exchange were evident in 
the children born very prematurely, especially those with BPD. Smoking in the family 
associated with decreased gas exchange, and these children should therefore be strongly 
advised against smoking or passive smoking. Impulse oscillometry yielded lung function 
information concordant with the conventional methods and served well in studying even 
children with neurological handicap or small lung volumes. 
To conclude, abnormal lung function, somatic growth and neurosensory development 
were common at school age in children born very prematurely. However, we found no 
negative effect associated with antenatal or neonatal DEX treatment. Less strenuous lung 
function methods, such as impulse oscillometry, help to assess the pulmonary disease of 
disabled or young children who cannot cooperate in conventional lung function studies. 
Despite the few abnormal findings, cardiac follow-up is important, as the chronic lung disease 
of prematurity may later in life lead to cardiac sequelae or mask the cardiac symptoms. If 
possible, very prematurely born children should also be protected from additional risk factors 
for impaired lung function, such as infections or smoking. 
 
   
 7
LIST OF ORIGINAL PUBLICATIONS 
 
This thesis is based on the following publications, which are referred to in the text by their 
Roman numerals (I to IV). 
 
I   Malmberg LP, Mieskonen S, Pelkonen A, Kari A, Sovijärvi AR, Turpeinen M. 
Lung function measured by the oscillometric method in prematurely born children 
with chronic lung disease. Eur Respir J  2000 Oct; 16(4): 598-603.  
II  Mieskonen ST, Malmberg LP, Kari MA, Pelkonen AS, Turpeinen MT, 
Hallman NMK, Sovijärvi AR. Exhaled nitric oxide at school age in prematurely 
born infants with neonatal chronic lung disease. Pediatr Pulmonol  2002 May; 
33(5): 347-355.  
III  Mieskonen S, Eronen M, Malmberg LP, Turpeinen M, Kari MA, Hallman M. 
Controlled trial of dexamethasone in neonatal chronic lung disease: an 8-year 
follow-up of cardiopulmonary function and growth. Acta Paediatr  2003 Aug; 
92(8): 896-904. 
IV  Mieskonen S, Kari MA, Eronen M, Malmberg LP, Turpeinen M, Hallman M. 
Randomized trial of antenatal dexamethasone before preterm birth: 
cardiopulmonary function, growth, and neurosensory outcome at 8 years.  
Submitted for publication. 
 
In addition, some unpublished data are presented. 
All refers to data of all study children born very prematurely.
   
 2 
ABBREVIATIONS 
 
 
AT  acceleration time 
ACTH adrenocorticotrophic hormone 
ASD atrial septal defect 
BPD bronchopulmonary dysplasia 
C  compliance 
CLD chronic lung disease 
COPD chronic obstructive 
pulmonary disease 
CP  cerebral palsy 
CPAP continuous positive airway 
pressure 
DEX dexamethasone 
∆FEV1 percentage change in FEV1 
from baseline 
DLCO pulmonary diffusing capacity 
∆Rrs5 percentage change in Rrs5 
from baseline 
∆Xrs5 percentage change in Xrs5 
from baseline 
ECG electrocardiogram 
ELBW extremely low birth weight, 
<1000 g  
eNO exhaled nitric oxide 
FEF50 forced expiratory flow at 50% 
of FVC 
FEF25-75 forced expiratory flow during 
the middle half of FVC  
FEV1 forced expiratory volume in 
one second 
FiO2 fraction of inspiratory oxygen 
FOT  forced oscillation technique  
FRC functional residual capacity 
fres resonance frequency 
FVC forced vital capacity 
 
 
 
IMV intermittent mandatory 
ventilation 
IOS impulse oscillometry 
IVH intraventricular hemorrhage 
KCO diffusing coefficient for 
carbon monoxide 
LBW low birth weight, <2500 g  
MEF maximal expiratory flow 
NEC necrotizing enterocolitis 
NO nitric oxide 
NOS nitric oxide synthase 
PAP pulmonary arterial pressure 
PDA patent ductus arteriosus 
PEF peak expiratory flow 
PVL periventricular leukomalacia 
Raw airway resistance 
RBBB right bundle branch block 
RDS respiratory distress syndrome 
ROP retinopathy of prematurity 
Rrs5 respiratory resistance at 5 Hz 
RV  residual volume 
RVET right ventricular ejection time 
SGA small for gestational age, birth 
weight <-2 SD from the mean 
birth weight for each 
gestational week  
SGaw specific conductance in the 
airways 
TGV thoracic gas volume 
TLC total lung capacity 
VC  vital capacity 
VLBW very low birth weight,  
<1500 g  
Xrs5 respiratory reactance at 5 Hz
Gaw airway conductance 
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INTRODUCTION 
 
Prematurity is a major cause of mortality and chronic morbidity in childhood. The outcome of  
preterm birth (<37 gestational weeks) depends on time and place. In developed countries, the 
survival of very low birth weight (VLBW, <1500 g) infants has increased, and their initial 
outcome has improved along with the advances in perinatal care (Lemons et al 2001, 
Saugstad 2001, Koivisto et al 2004). However, their infant mortality rate, i.e. death until one 
year of age per 1000 live births, is more than 100-fold compared to infants with normal birth 
weight. Neonatal deaths during the first four weeks of life account for two thirds of overall 
infant mortality, and half of the deaths take place during the first week of life. (Mathews et al 
2003) Neonatal mortality of VLBW infants is highest during the first few days of life, mainly 
due to respiratory distress syndrome (RDS), infections and immaturity (Stevenson et al 1998). 
In a recent Finnish study of extremely low birth weight (ELBW, <1000 g) infants, neonatal 
mortality was 38%. Perinatal mortality (death from the 20th week of gestation to seven days of 
age) was 55%, accounting for 39% of all perinatal deaths. (Tommiska et al 2001) In a large 
multicenter study of VLBW infants in 1989-1990, 78% survived until discharge (Hack et al 
1995); in 1995-1996, 84% survived (Lemons et al 2001). In Finland, 834 VLBW infants were 
born alive in 1987 and 611 in 2003, accounting for 1.4% and 1.0% of live births, respectively 
(Stakes 2004).  
 
The clinical course and definitions of bronchopulmonary dysplasia (BPD), also called the 
chronic lung disease (CLD) of prematurity, have changed over time, but with no clear decline 
in incidence (Parker et al 1992). Besides BPD, defined as a need for supplemental oxygen at 
36 postconceptional weeks in the present study (Shennan et al 1988), periventricular brain 
damage, including intraventricular-periventricular haemorrhage (IVH) and periventricular 
leukomalacia (PVL), necrotizing enterocolitis (NEC) and retinopathy of prematurity (ROP) 
cause severe morbidity in VLBW infants. Pulmonary problems persist well beyond the 
neonatal period or infancy. They may be associated with disturbances in growth, cardiac 
function and neurodevelopment that may continue until school age or adulthood. 
 
The pathogenesis of BPD is multifactorial and incompletely understood. Immaturity, oxygen 
toxicity, baro/volutrauma and other perinatal factors, such as infection, promote lung injury. 
Inflammation plays an important role in the progress of initial changes into a chronic lung 
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disease. In the less mature survivors, BPD is characterized by an arrest in lung development, 
including minimal alveolarization and impaired vascular growth. (Jobe 1999) 
 
Dexamethasone (DEX) and betamethasone are synthetic glucocorticoids with multiple acute 
beneficial effects on immature lung (Ballard & Ballard 1995). In 1972, Liggins and Howie 
showed that maternal treatment with betamethasone before preterm birth reduced the rate of 
RDS and neonatal death. This result was confirmed more extensively in multiple trials during 
the following years (Crowley 1995), and antenatal glucocorticoid therapy is now 
recommended for women at risk of delivery at 24-34 gestational weeks (National Institutes of 
Health, NIH 1995).   
 
An early trial with hydrocortisone as treatment of RDS revealed no significant benefits 
(Baden et al 1972). In the 1980´s, DEX treatment for severe BPD was found to decrease the 
time on mechanical ventilation and supplemental oxygen (Mammel et al 1983, Avery et al 
1985). With growing evidence of the inflammatory basis of BPD, DEX was considered as an 
early treatment of very high-risk infants (Yeh et al 1990). However, treatment after birth was 
associated with severe side effects, and animal experiments provided evidence of abnormal 
brain growth and development after corticosteroids (Whitelaw & Thoresen 2000). The 
widespread use of glucocorticoids postnatally and even antenatal use, particularly as multiple 
courses, evoked concern about long-term adverse effects. After the initiation of our study, 
early treatment with postnatal DEX was shown to associate with an increased risk of cerebral 
palsy (CP) and a delay in neurodevelopment (Yeh et al 1998, O´Shea et al 1999, Shinwell et 
al 2000). New guidelines limited the use of DEX to exceptional circumstances, i.e. infants on 
maximal ventilatory and oxygen support (American Academy of Pediatrics, AAP 2002), but 
the final role of postnatal corticosteroid is still undefined (Halliday 2003). Although antenatal 
DEX treatment was associated with serious adverse consequences, long-term data after 
antenatal or neonatal glucocorticoid trials are sparse or completely missing. 
 
The lung function of prematurely born children cannot usually be assessed until school age, 
since the conventional tests require considerable cooperation. Even then, the examinations 
may be hampered by neurological disabilities and small lung volumes. The forced oscillation 
technique (FOT) and impulse oscillometry (IOS), a modification of FOT, enable the 
measurement of lung function during normal quiet tidal breathing. They therefore require 
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only minimal cooperation and are suitable at preschool age. Scant FOT data are available on 
prematurely born children (Duiverman et al 1988).  
  
Inhaled glucocorticoid treatment of low birth weight (LBW) children had no effect on the 
baseline lung function or the airway response to histamine at school age in one study, arguing 
against an inflammatory basis of airway hyperresponsiveness (Chan & Silverman 1993). 
However, changes in T lymphocyte subsets, with an association with bronchial lability, 
suggested that the abnormal immunological alteration may be related to BPD (Pelkonen et al 
1999). Measurement of the exhaled nitric oxide (eNO) concentration has been proposed as a 
non-invasive method to assess airway inflammation in asthma (Alving et al 1993, Lundberg 
et al 1996) and disease activity in chronic obstructive pulmonary disease (COPD) (Maziak et 
al 1998). ENO has been associated with eosinophilic inflammation in the lungs (Piacentini et 
al 1999, Mattes et al 1999), but the role in non-atopic asthma remains undefined. No reports 
exist of eNO in school-aged children with BPD.   
 
In the present follow-up study of two randomized placebo-controlled trials, we evaluated the 
effect of antenatal or neonatal DEX on cardiopulmonary function, growth and neurosensory 
development at school age in children born very prematurely. Elaborate non-invasive methods 
were used to measure lung function, exhaled NO and cardiac function.  The children born 
very prematurely were born very preterm (<31 gestational weeks) as well as with a very low 
birth weight (<1575 g) in 1989-1991. 
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REVIEW OF LITERATURE 
 
1.  Human lung growth and development 
 
Normal lung development during organogenesis can be divided into five stages (Burri 1997, 
Kotecha 2000). During the embryonic stage (3-7 weeks of gestation), the lung develops as an 
outgrowth of the ventral wall of the primitive foregut endoderm. Epithelial cells from the 
endoderm invade the surrounding mesoderm to form the proximal structures of the respiratory 
tract: the trachea, main bronchi, five lobes and 18 major lobules. The pulmonary arteries 
develop to accompany the branching airways. During the pseudo-glandular stage (7-16 
weeks), the epithelial tubules are surrounded by thick mesenchymal tissue, and the conducting 
airways, terminal bronchioles and primitive acinus are formed. The pseudo-stratified 
columnar epithelium is progressively replaced by tall columnar cells in the proximal airways 
and cuboidal cells in the distal acinar structures. During the canalicular stage (16-26 weeks), 
primary acini develop, consisting of respiratory bronchioles, alveolar ducts and rudimentary 
alveoli. The intra-acinar capillaries derive from the surrounding mesenchyme. Many cells in 
the distal epithelium differentiate into lamellar body-containing cells resembling type II 
pneumocytes. During the saccular stage (24-36 weeks), the peripheral airways enlarge as the 
acinar tubules dilate and the walls become thinner, resulting in increased gas-exchanging 
surface area. Lamellar bodies increase, and terminal differentiation of type II cells into type I 
pneumocytes takes place. Capillaries closely associated with type I cells reduce the distance 
between the future air-blood interface. During the alveolar stage (32 weeks - 10 years), the 
secondary alveolar septa are formed. Mesenchymal cells proliferate to deposit the 
extracellular matrix, epithelial cells (type I and type II pneumocytes) line the alveolar walls, 
and endothelial cells grow into the secondary septa and, after remodelling, form a single 
capillary loop. This maturation results in a marked increase in gas-exchanging surface area, as 
the estimated 20 to 50 million alveoli present at birth increase to 300 million by adulthood.  
 
Factors affecting lung growth and development 
Data on lung growth are mainly derived from studies of animals with differences in timing of 
lung maturation.  Different mechanisms and a number of hormones, growth factors, cytokines 
and transcription factors are involved in normal lung growth, differentiation and repair 
processes after lung injury. (Kotecha 2000) 
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During the canalicular stage, pulmonary hypoplasia may be secondary to oligohydramnion 
as a result of prolonged rupture of membranes, to the restriction of fetal breathing movements 
or to space-occupying abdominal organs in diaphragmatic hernia. Severe pulmonary 
hypoplasia leads to severe respiratory distress because of poorly developed peripheral airways 
and small lung size. On the other hand, overdistention of the lung by fluid seems to improve 
lung growth by releasing many growth factors. Severe malnutrition decreases lung volumes 
without interfering with maturation, whereas postnatal food restriction may exacerbate severe 
lung injury and resistance against toxic agents, such as hyperoxia. (Kotecha 2000) 
Glucocorticoids are involved in both lung growth and differentiation. A genetic lack of 
glucocorticoid receptor in fetal mice results in hypoplastic immature lungs and impaired gas 
exchange at term birth (Cole et al 1995). Glucocorticoids bind with high affinity to 
cytoplasmic receptors, and the activated steroid-receptor complex binds to several response 
elements in the promoters of a number of genes profoundly influencing transcription. 
Glucocorticoid activity partly controls the synthesis and secretion of alveolar surfactant. 
Furthermore, the increase in compliance and maximal lung volume, the decrease in vascular 
permeability, the maturation of the parenchymal structure and the clearance of lung water are 
controlled by glucocorticoids, adrenergic agents and other agonists. (Ballard & Ballard 1995, 
Mallampalli et al 1997, Jobe & Bancalari 2001)  
 
2.  Respiratory distress syndrome (RDS) 
 
Clinical presentation and pathology 
RDS in the premature infant presents with an acute, severe respiratory distress and 
requirement for supplemental oxygen shortly after birth. The chest radiograph shows 
increased density in the lung fields with fine granularity, air bronchograms and elevation of 
the diaphragm, indicating generalized atelectasis and lung oedema. Traditionally, the severity 
increases for three days, and normal lung function is restored within a week. Nearly all infants 
die with supportive care only, and about 50% die with the administration of supplemental 
oxygen alone. In infants <32 gestational weeks, who rarely survive without ventilation using 
continuous distending pressures, the condition is usually prolonged and commonly involves 
pulmonary complications, such as pneumothorax, pulmonary interstitial emphysema and 
infection. Immaturity of the lung and the cardiovascular system (leaky pulmonary capillaries 
shortly after birth, immature pulmonary connective tissue, compliant chest cage, patency of 
ductus arteriosus, immature host defence against microbes and other external noxious agents) 
   
 11
further predispose these infants to lung injury. RDS is a major risk factor of BPD and IVH 
and involves significant mortality. (Bancalari & Bidegain 1999)   
 
Pulmonary surfactant 
In 1959, Avery and Mead discovered evidence of deficient surface activity in lung lavage of 
infants dying of hyaline membrane disease. These findings marked the beginning of 
systematic research leading to the introduction of surfactant therapy for RDS and further 
therapeutic applications. Lung surfactant is needed to decrease surface tension and to prevent 
the collapse of the small airways. The composition of surfactant, as reviewed by Jobe (1993a) 
and Hallman et al (2001), consists of specific phospholipids (85-95%), neutral lipids (3-8%) 
and specific proteins (5-10%). Of the four identified surfactant-associated proteins, SP-A 
improves surface properties and has roles in pulmonary host defence. The lipophilic proteins 
SP-B and SP-C facilitate rapid adsorption and spreading of surfactant phospholipids to the 
gas-liquid interface. The timetable of the maturation of the human lung and surfactant system 
is highly variable. Generally, it takes place before term, increasing towards term. 
RDS is caused by a deficiency in alveolar surfactant due to immaturity of alveolar type II 
epithelial cells. Many premature infants have sufficient quantities of surfactant in the airways 
and do not develop RDS, even when born after only 65-80% of the pregnancy has lapsed. 
(Hallman et al 2001) The antenatal development of surfactant secretion corresponds closely to 
the risk of RDS, and the suspectibility to RDS is influenced by variations in the SP-A and SP-
B genes, race, sex and perinatal complications. Besides providing alveolar stability, individual 
components of surfactant have important roles in the innate immune response and in the 
defence against microbes. (Marttila et al 2003b, Marttila 2003a, Hallman et al 2002)   
 
Surfactant therapy 
The first pilot study of exogenous surfactant given to severely ill preterm infants in 1980 
(Fujiwara et al) was soon followed by randomized clinical trials on exogenous surfactant 
from human amniotic fluid, from mammalian lungs or from broncho-alveolar lavage fluid and 
on synthetic surfactant (Merritt & Hallman 1988). Surfactant therapy ameliorates or prevents 
the expiratory failure dramatically when administered into the airways in RDS or at very 
premature birth. Neonatal mortality decreased by 45-55% and serious pulmonary air leak by 
50-80%. Since the early 1990´s, administration of animal-based or synthetic surfactant into 
the airways has been an approved treatment of RDS, and it has since been accepted into 
common use as effective and life-saving treatment. (Hallman et al 2001) As more and more 
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very immature infants survive, there has been no significant decrease in the incidence of BPD 
or patent ductus arteriosus (PDA) or IVH (Jobe 1993a). 
 
Incidence and prevention of RDS  
Despite surfactant and antenatal glucocorticoid treatments (Chapter 10.2.), RDS remains a 
major cause of mortality and morbidity, as the survival of more immature infants increases. In 
Finland, the incidence of RDS increased during the 1960-1970´s, but remained stable from 
1990-1995 to 1996-1999 (8.7-7.6 per 1000 livebirths). The gestational-age-specific incidence 
of and mortality from RDS decreased, but still accounted for 15% of neonatal deaths. 
(Koivisto et al 2004) In the USA, in an inborn cohort of 4438 infants in 14 centres (1995-
1996), RDS occurred in 50% of VLBW infants and in 78% of those with 501-750 g birth 
weight (Lemons et al 2001). In a Finnish national study (1996-1997), the neonatal mortality 
of ELBW infants was 38%, and in 39% of the cases the reported leading cause of death was 
RDS. In that study, of the infants surviving >12 hours, 76% had RDS, and 74% of those <30 
weeks of gestational age received surfactant. (Tommiska et al 2001)   
Expectant management of high-risk pregnancies, analysis of fetal lung maturity, 
avoidance of near-term caesarean sections without labour and glucocorticoid treatment in 
imminent preterm birth (<34 gestational weeks) are practices that decrease the risk of RDS 
(Hallman 1992a, Crowley 2000). 
 
3.  Bronchopulmonary dysplasia (BPD) 
 
Old BPD 
BPD was first described by Northway et al in 1967 as a severe lung injury in mechanically 
ventilated large preterm infants, who required 80-100% oxygen and had a prolonged course of 
severe respiratory distress. The clinical, radiological and pathological progression of the 
primary lung disease had several stages. The initial RDS (stage I, days 1-3) was characterized 
by severe diffuse lung disease. It was followed by increasing opacification of the lungs, 
corresponding to pathological findings of exudation in the airways and patchy bronchiolar and 
alveolar epithelial necrosis (stage II, days 4-10). Stage III (days 10-20) was a transition to 
chronic lung disease with small, round areas of radiolucency alternating with areas of sponge-
like irregular density in chest radiographs, representing emphysematous alveoli adjacent to 
atelectatic alveoli, and pulmonary fibrosis. At stage IV (after 30 days), chronic lung disease 
with hyperexpansion and larger cysts became evident in the basal lung fields. This stage was 
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frequently accompanied by right ventricular hypertrophy and cardiomegaly with cor 
pulmonale. Pathologically, emphysema with thickened lung interstitium, dysplastic airways 
and lung vasculature were frequently evident. (Northway et al 1967, Northway 1990a) 
  
Changing BPD 
In the 1970´s, BPD was defined as a respiratory failure in the neonatal period requiring 
assisted ventilation for at least three days, with persistent respiratory symptoms and 
radiological findings and oxygen dependency at four weeks of age (Bancalari et al 1979, 
Tooley 1979, Edwards 1979a). In the 1980´s, with improvements in the ventilation techniques, 
the survival of infants <1000 g increased, and oxygen concentrations and peak inspiratory 
pressures decreased, modifying the radiological changes into a fine reticular pattern, with or 
without hyperexpansion (Northway 1990a). O´Brodovich & Mellins (1985) reviewed BPD 
and suggested it to represent a non-specific reaction of the lung to slowly resolving acute 
injury. Hyperinflation was seen as the predominant radiographic abnormality along with 
chronic respiratory difficulties, prolonged and recurrent hospitalization, neurodevelopmental 
disabilities and growth restriction associated with BPD. In VLBW infants, apart from 
classical coarse reticulation, a milder type with homogenous or patchy opacification, 
particularly perihilar, was present in radiographs (Hyde et al 1989), and the pathological 
progression of lung injury differed from that originally seen: a largely parenchymal picture 
with marked increases in interstitial elastic tissue, less severe squamous metaplasia and poor 
development and simplification of the terminal respiratory unit (Chambers & van Velzen 
1989). 
With the survival of increasingly immature infants, the criterion of supplemental oxygen 
at 28 days became insufficient in anticipating long-term morbidity. In 1988, Shennan et al 
proposed that the need for supplemental oxygen at 36 gestational weeks was a better predictor 
of abnormal outcome during the first two years of life. This criterion was adopted into wide 
use, and it is often also referred to as chronic lung disease (CLD).                         
Palta et al (1998) compared different criteria, such as supplemental oxygen and/or 
radiograph or a severity score based on oxygen need, ventilatory variables, blood gases and 
radiograph at 30 days of age, and supplemental oxygen at 36 gestational weeks. All criteria, 
especially the radiographic ones, were predictive of long-term outcome at five years of age, 
but the combination of radiograph and supplemental oxygen at 36 weeks was proposed. 
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prominent findings, accompanied by early vascular lesions, right ventricular hypertrophy and 
cardiomegaly with cor pulmonale. Infants dying of BPD in the era of surfactant treatment had 
fewer and larger alveoli with less fibrosis and inflammation than in the past (Husain et al 
1998, Jobe & Bancalari 2001), and alveolar hypoplasia was accompanied by bronchial 
smooth muscle hypertrophy and bronchial gland hyperplasia, contributing to airflow 
limitation (Margraf et al 1991). Preterm baboons (75% of gestation) exposed to 100% oxygen 
and mechanical ventilation, used to model the old BPD, had a lower alveolar number at the 
age of 33 weeks compared to those ventilated with clinically appropriate oxygen (Coalson et 
al 1995). Similar pathology was seen in baboons delivered extremely preterm (67% of 
gestation) after prenatal glucocorticoid, surfactant treatment and mechanical ventilation with 
even less than 50% oxygen (Coalson et al 1999). The new BPD is characterized by an 
arrest of lung development with minimal alveolarization, less airway epithelial disease and 
less interstitial fibrosis (Jobe 1999), with dysmorphic capillary configurations (Coalson 2003). 
The predominant pathogenetic factor in BPD is a recurrent inflammatory reaction, 
whether provoked by an intrauterine infection or inflammation that persists after birth or 
caused by neonatal damage to the airways and airspaces due to hypoxia, 
barotrauma/volutrauma or infection (Groneck & Speer 1995, Watterberg et al 1996, Speer 
1999, Hallman et al 2001). Other antenatal or postnatal factors, such as intrauterine growth 
retardation, preeclampsia, drugs or malnutrition may also affect the risk of BPD (Kotecha 
2000). 
 
Oxygen toxicity  
Preterm infants are predisposed to changing levels of supplemental oxygen and mechanical 
ventilation soon after birth, as reviewed by Barrington & Finer (1998), Kotecha & Silverman 
(1999) and Jobe & Bancalari (2001). According to the traditional view, BPD is caused 
primarily by oxidant- and ventilation-mediated injury. In animal studies, oxygen can arrest the 
septation of lungs at the saccular stage (Coalson et al 1995), with more impairment at higher 
oxygen levels (Coalson et al 1999). 
High concentrations of oxygen induce lung inflammation and may lead to chronic fibrotic 
and destructive changes, as the production of reactive oxygen species and the release of 
chemotactic factors lead to the release of inflammatory mediators and proteolytic enzymes. 
The low levels of antiproteases and antioxidant enzymes in the serum and lung of preterm 
infants result in increased susceptibility to oxygen toxicity and to BPD. (Barrington & Finer 
1998) 
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Barotrauma - volutrauma   
Multiple factors act additively or synergistically to promote lung injury. The initiation of 
mechanical ventilation causes a proinflammatory response. In preterm baboons, mechanical 
ventilation even without high levels of oxygen may result in the pathologic lesion of BPD 
(Coalson et al 1999). Although the exact mechanisms of lung injury are unknown, attempts to 
reduce barotraumas are suggested to reduce the incidence of BPD (Kotecha & Silverman 
1999). The avoidance of intubation and mechanical ventilation by administering continuous 
positive airway pressure (CPAP) in the delivery room has been associated with a lower 
incidence of BPD (Avery et al 1987, Van Marter et al 2000).  
 
Inflammatory injury  
Pulmonary inflammation is maximal at 7-10 days in infants who develop BPD (Vyas & 
Kotecha 1997), as evidenced by the increase in neutrophils and multiple proinflammatory and 
chemotactic factors present in the airspaces of ventilated preterm infants (Merritt et al 1983, 
Groneck & Speer 1995, Vyas & Kotecha 1997). Infants exposed to chorioamnionitis had IL-
1β more frequently present in their tracheal fluid from the first day, which associated with the 
development of BPD, despite the lower risk of RDS (Watterberg et al 1996). Colonization of 
the airways of preterm infants with Ureaplasma urealyticum associated with acute respiratory 
insufficiency (Ollikainen et al 1993); others found protection against RDS, but an increase in 
BPD (Hannaford et al 1999). Chemotaxis of inflammatory cells and release of cytokines and 
other mediators may cause lung injury and initiate the repair process. The same factors may 
be released in nosocomial pneumonia. (Barrington & Finer 1998) 
In very preterm born baboons, significant elevations of certain proinflammatory cytokines 
(TNF-α, IL-6, IL-8, but not IL-1β and IL-10) in tracheal aspirate fluids were present at 
various times during ventilatory treatment, supporting a role for mediator-induced 
autoinflammation; IL-8 was elevated mostly in the presence of significant lung infection 
(Coalson et al 1995). Preterm lung contains very few macrophages or granulocytes. 
Granulocytes appear in the lung soon after the initiation of ventilation in animals (Carlton et 
al 1997), which correlates with pulmonary oedema and the appearance of early indicators of 
injury and occurs parallel to a decrease in circulating granulocytes. This decrease in 
granulocytes at one hour of age associates with an increased risk of BPD (Ferreira et al 2000). 
Proteases produced by activated white blood cells in the lung may contribute to the 
progression of lung injury. 
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Vascular injury 
Pulmonary vascular resistance is often increased in infants with BPD, and decreased vascular 
development may be important in the pathopsysiology of BPD (Jobe & Bancalari 2001). The 
vascular injury may result from direct toxicity of stimuli, such as oxygen and mechanical 
ventilation, to the developing vasculature or from the release of toxic inflammatory mediators. 
Damage to the developing alveolar epithelium is suggested to interrupt the signalling between 
vascular endothelial growth factor (VEGF) and its receptors and to result in abnormal 
pulmonary capillary growth and function. Converse theories suggest that the primary 
disruption of pulmonary vascular development impairs alveolarization and may result in 
histologic changes similar to BPD. (Parker & Abman 2003) Low VEGF levels in tracheal 
aspirates have been found in preterm infants who later develop BPD (Lassus et al 1999), 
while high levels have been seen in infants treated with DEX (D´Angio et al 1999). 
 
Surfactant dysfunction 
The recovery of surfactant phospholipids during the first week of life among infants who 
develop BPD is not strikingly different from those who have an uncomplicated course of 
RDS. The most clearly detectable difference, low surfactant phosphatidylinositol in infants 
developing BPD, was eliminated by inositol supplementation at birth. (Hallman et al 1992b) 
Infants developing BPD also had very low SP-A levels in airway specimens, but according to 
recent evidence, surfactant dysfunction in infants developing BPD is not prevented by 
surfactant therapy (Hallman et al 2001).  
 
Genetic predisposition  
Genetics may contribute to BPD at multiple levels (Marttila 2003a). According to an early 
study, HLA-A2 is associated with susceptibility to BPD (Clark et al 1982). The 
alleles/genotypes of SP-A, SP-C or SP-D associate with the risk of inflammatory lung and 
airway diseases. Rare mutations in SP-B and SP-C cause serious, often fatal, lung diseases 
(Hallman et al 2002, Marttila 2003a, Hallman 2004). Thus far, one allelic variant of the 
surfactant protein B gene (intron 4 deletion variant) has been shown to associate with an 
increased risk of BPD (Rova et al 2004).   
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3.2.  Incidence of BPD 
 
The original BPD occurred in 11-21% of mechanically ventilated infants and in 1-8% of all 
infants with RDS (Northway 1979), showing a relationship with low birth weight: 38% of 
survivors of RDS with birth weights of 750-1500 g had BPD compared with less than 10% of 
those >1500 g (Tooley 1979). Even after controlling for birth weight, race and sex, the 
incidence at 28-30 days varied among intensive care units, correlating with differences in 
treatment (Avery et al 1987, Horbar et al 1988, Kraybill et al 1987, Kraybill et al 1989). In 
ELBW infants after mechanical ventilation, the most powerful predictors of BPD were male 
sex and lower PaCO2 at 48 hours, indicating that it might be possible to reduce the risk by 
adjusting ventilation (Kraybill et al 1989). The incidence of BPD at 28 days in VLBW infants 
increased from 11% in the late 1970´s to 33% in the late 1980´s, mostly but not exclusively 
due to improved survival. The increase persisted even with the criterion of oxygen at 36 
gestational weeks for infants <32 gestational weeks at birth. Gestational age was a significant 
predictor of BPD after adjustment for birth weight. (Parker et al 1992) In a Finnish study of 
VLBW infants born in one hospital in 1990-1994, 31% of the surviving infants had BPD, i.e. 
supplemental oxygen with radiographic changes, at 28 days and 13% at 36 gestational weeks. 
Besides low birth weight and gestational age, early weight gain, preeclampsia and possibly 
intrauterine growth retardation were important risk factors for BPD at 36 weeks. (Korhonen et 
al 1999b)     
BPD is currently rare in infants with >1200 g or >30 gestational weeks at birth, as gentler 
ventilation techniques, antenatal glucocorticoids and surfactant treatment have minimized 
severe lung injury. However, BPD is the most common complication in ELBW infants (Jobe 
1999, Jobe & Bancalari 2001), and it may also occur in infants with minimal or no lung 
disease initially (Charafeddine et al 1999), some of them exposed to chorioamnionitis 
(Watterberg et al 1996). In the NICHD multicentre study (1995-1996), the incidence of BPD 
at 36 weeks was 23% in surviving infants with birth weights of 501-1500 g, with a slight 
increase over five years (19-23%, survival 80-84%); the incidence increased markedly with 
decreasing gestational age, and nearly all survivors with birth weight of 400-500 g had BPD 
(Lemons et al 2001). In comparison, of the VLBW infants born in 1989-1990, 78% survived 
and 8% of the survivors had BPD (Hack et al 1995). Thus, no evidence suggests a decline in 
the incidence of BPD. 
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3.3.  Prevention and treatment of BPD 
 
The prevention of preterm births and various maternal conditions harmful for the fetus is a 
continuing challenge, with major effects on the development of BPD. O´Brodovich & Mellins 
(1985) presented that the means to treat BPD are identical to those initiating the injury. 
Despite the advances in perinatal care, the means to prevent and treat BPD are still 
unsatisfactory, as reviewed by Barrington & Finer (1998) and more recently by Korhonen 
(2004a).  
 
Optimization of oxygen administration  
As far as possible, high oxygen concentrations should be avoided in the treatment of preterm 
infants. However, the saturation target range is still controversial. (Kotecha & Allen 2002, Tin 
2004) Exogenous surfactant should be administered to intubated VLBW infants with 
significant lung disease prior to two hours of age, to reduce the need for oxygen and 
ventilatory support, even though no clear effect is seen in the incidence of BPD (Jobe & 
Bancalari 2001). In BPD infants, avoidance of hypoxia is important, to alleviate the 
progressive muscularisation of small pulmonary arteries and enhanced vasoreactivity (Parker 
& Abman 2003). According to the present proposal, O2 saturations of 94-96% should be 
aimed at for infants with established BPD who are not at risk of further progression of ROP 
(Kotecha & Allen 2002). 
 
Antioxidant therapy 
Hyperoxic lung injury may be ameliorated in animals by the administration of exogenous 
antioxidants, such as recombinant superoxide dismutase. In humans, no difference in the 
primary outcome of death and/or BPD was found, but IVH and PVL were less severe. 
(Barrington & Finer 1998) Nor did N-acetylcysteine prevent BPD (Ahola et al 2003). Specific 
nutrients, such as vitamins and cofactors, may also function in antioxidant defence (Kotecha 
& Silverman 1999). Despite initial suggestions, vitamin E supplementation failed to show 
benefits in reducing BPD (Jobe & Bancalari 2001).   
 
Mode of ventilation  
Different modes of ventilation have been used to minimize baro- and volutrauma, but none of 
them have proven superior to the others (Henderson-Smart et al 2004). In 1963, the first 
infant survived intubation and ventilation without air leak or cerebral abnormalities 
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(McGettigan et al 1998). Since 1971, CPAP has been used to treat infants with RDS (Mariani 
& Carlo 1998), and it is considered to lower the risk of BPD by reducing barotrauma (Avery 
et al 1987). Since that time, ventilation with continuous distending pressures has been the 
basis of neonatal ventilatory support. During intermittent mandatory ventilation (IMV), 
asynchronous breathing may result in irregular systemic and cerebral flow patterns, air leak 
and neurological complications. In 1986, patient-triggered ventilation was first described: 
synchronous IMV (SIMV), assist control and pressure support ventilation were further 
developed. However, conventional mechanical ventilation still induced severe lung injury.  
High-frequency oscillatory ventilation, using very low tidal volumes, is used to rescue 
patients and to avoid lung injury in severe respiratory distress. (McGettigan et al 1998) 
Assisted ventilation is recommended to be used with the lowest possible pressures required 
for adequate gas exchange, in the most gentle ways available, followed by weaning and 
extubation as soon as possible, allowing moderate hypercarbia. Nasal CPAP at birth or after a 
brief period of ventilation is currently studied as a non-invasive method of ventilation. (Avery 
et al 1987, Kraybill et al 1989, Barrington & Finer 1998) 
 
Infection / inflammation  
Infection may contribute to the development of inflammation with an adverse effect on lung 
growth and pulmonary defence functions (Watterberg et al 1996). The prevention and 
treatment of perinatal and nosocomial infections have been studied in relation to BPD. 
Prevention of later infections by immune globulins, including those against respiratory 
syncytial virus, and vaccinations are considered to reduce further risks for the lung in BPD. 
Anti-inflammatory agents have been used in treatment (sodium cromoglycate, 
glucocorticoids). (Barrington & Finer 1998) 
 
Pulmonary vascular resistance 
In infants with severe RDS, vasodilators, such as inhaled nitric oxide, can be used along with 
oxygen therapy to decrease pulmonary vascular resistance. Inhalation of NO may improve 
oxygenation and decrease the risk of BPD by minimising intra- and extrapulmonary shunting 
and by decreasing inflammation. (Jobe & Bancalari 2001) 
 
Nutrition and growth 
Nutrition plays a supportive role in normal lung development and maturation. General 
undernutrition, especially insufficient protein intake, may increase the vulnerability to 
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oxidant-induced lung injury. (Jobe & Bancalari 2001) Inositol (Hallman et al 1992b), vitamin 
A (Tyson et al 1999) and retinoic acid have been studied in experimental models of lung 
injury (Massaro & Massaro 2000). Supplementation of inositol (Hallman et al 1992b) or 
vitamin A (Tyson et al 1999) to small preterm infants may reduce the risk of BPD, although 
the evidence is not convincing. Nutrition should be optimized early after birth but probably 
with some delay in intravenous lipid administration until pulmonary vascular resistance has 
decreased (Barrington & Finer 1998).  
Growth failure is common in infants with severe BPD (Northway 1979, Markestad & 
Fitzhardinge 1981,Yu et al 1983), possibly because of their increased energy expenditure and 
high metabolic rate. Hypoxemia, gastroesophageal reflux, poor feeding with inadequate 
nutritional intake, heart failure, neurodevelopmental handicap and socioeconomic factors 
further predispose BPD infants to unsatisfactory growth (Kotecha & Silverman 1999). 
However, data on the ability of optimal growth and nutrition to improve long-term outcome 
are sparse. 
 
Improving respiratory mechanics, prevention of oedema 
Bronchodilating agents improve lung mechanics in ventilator-dependent infants, but their 
long-term effects are unknown. Methylxanthines (theophylline) are used to prevent apnoea in 
preterm infants, but they also function as bronchodilators and diuretics. Increased fluid intake 
may aggravate pulmonary oedema directly or by increasing the incidence of PDA (Kotecha & 
Silverman 1999). Relative fluid restriction in very preterm infants at risk for BPD decreased 
both mortality and BPD rates (Tammela & Koivisto 1992). Interstitial lung water can be 
reduced by loop diuretics (furosemide), which decrease pulmonary resistance and increase 
dynamic compliance. Non-loop diuretics (hydrochlorothiazide and spironolactone) improve 
lung mechanics, but with no consistent long-term benefit. In BPD, furosemide and inhaled 
bronchodilator agents are considered to allow weaning and extubation of ventilator-dependent 
infants. (Barrington & Finer 1998)  
 
Glucocorticoids 
Glucocorticoids serve as anti-inflammatory and antioedematic agents. They accelerate the 
differentiation of immature lung by increasing the synthesis and secretion of lung surfactant 
and the activity of antioxidants. However, they also interfere with alveolarization and 
angiogenesis (See Chapter 9 and 10). Antenatal glucocorticoids should be used in imminent 
preterm delivery to attenuate initial respiratory distress (Crowley 1995, NIH 1995). Inhaled 
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glucocorticoids have been used to shorten the duration of mechanical ventilation (Cole et al 
1999, Shah et al 2003). Postnatal glucocorticoid treatment may be considered in severely ill, 
ventilator-dependent infants to facilitate weaning (AAP 2002). However, no clear decline has 
been seen in the incidence of BPD after either modality of glucocorticoid treatment. 
 
4.  Respiratory morbidity in children born prematurely 
 
The survivors of old BPD born in the 1960-1970´s frequently had persistent respiratory 
symptoms at school age (Smyth et al 1981) and more wheezing, upper respiratory tract 
infections, pneumonia, limitations of exercise capacity and long-term medication than full-
term controls at school age (Bader et al 1987) or preterm born adolescents with no BPD 
(Northway et al 1990b). 
 
In the late 1970´s, mechanically ventilated VLBW infants had tracheobronchial 
hypersecretion and frequent lower respiratory infections during the first year of life. The need 
for hospitalization was associated with male gender, CPAP, mechanical ventilation and 
oxygen therapy. (Wong et al 1982a) Myers et al (1986) used regular physical examination, 
respiratory illness score and viral cultures until the age of one year to show that LBW infants 
(<2000 g) with or without RDS did not have an increased risk for respiratory illness compared 
with full-term controls. However, the RDS survivors, particularly those with BPD, 
experienced their lower respiratory tract infections earlier and with more severe symptoms 
than the controls. 
A prospective cohort study compared LBW children (<2000 g) with unselected 
schoolchildren using questionnaires. Wheezing (16%) and troublesome cough (17%) were 
common in healthy schoolchildren. There were no differences in maternal smoking (40%) or 
the family history of asthma (12%) between the LBW and control children. However, 
whooping cough, previous chest infection and previous admission into hospital for chest 
illness were twice as common in the LBW cohort than in the controls. Oxygen 
supplementation, mechanical ventilation and BPD increased the rate of chest infections during 
the first two years (30% in the BPD group) and also increased admission into hospital for 
respiratory infection (40% in the BPD group). In the subgroup of VLBW children after 
neonatal respiratory treatment, frequent and troublesome cough was more common at seven 
years than in unselected controls. No excess of wheezing, but a weak correlation between 
wheezing and the oxygen score, or absence from school due to respiratory symptoms was 
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found in LBW children. Wheezing associated with maternal smoking.  Of the VLBW 
children, those with BPD had a high prevalence of symptoms, but they did not differ 
significantly from the non-BPD group. (Chan et al 1989a) 
Another study confirmed the previous findings of excess respiratory morbidity associated 
with mechanical ventilation in children born very prematurely, particularly during the first 
two years, but found dyspnea to be uncommon at school age. BPD children needed 
adenoidectomy and tympanostomy tubes more commonly. (Hakulinen et al 1990) At 
preschool age, BPD children had an increased risk for respiratory infections compared to 
controls born at term, with no significant difference compared to non-BPD children 
(Korhonen et al 1999a). In a prospective study, the persistence of respiratory symptoms into 
the second year of life was associated with mechanical ventilation, supplemental oxygen, air 
leak and increased resistance in body plethysmography at six months (Yuksel & Greenough 
1992). 
In ELBW survivors, clinical respiratory health at the age of 14 years, based on wheezing 
requiring bronchodilators or readmissions into hospital for pneumonia or asthma, was found 
to be similar to normal birth weight controls, despite differences in lung function (Doyle 
2000a). 
  
The studies of VLBW children born in the 1980´s have mainly used the criterion of oxygen at 
36 weeks for BPD. In a Finnish study, half of the VLBW children had had dyspneic 
symptoms, and two out of 29 had suffered from prolonged coughing (>3 weeks) during the 
previous year. Atopy was diagnosed in 17% of the BPD and 29% of the non-BPD children; in 
their families, atopy (41% vs 50%) and smoking (50%) were common. (Pelkonen et al 1997)  
Others found atopy less often in VLBW children (15%) at ten years than in full-term  controls 
(31%) (Siltanen et al 2001), and the lifetime prevalence of wheezing was 43% vs 17%, 
respectively (Siltanen et al 2004). After severe BPD requiring oxygen at home, the children 
had a higher incidence of activity limitation because of their respiratory symptoms than non-
BPD controls at the age of 11 years (Jacob et al 1998). Children born very preterm (<32 
gestational weeks), especially those with BPD, required more hospitalizations during the first 
two years than their full-term controls. Wheezing and chronic cough were common at school 
age, with no differences between the BPD and non-BPD groups, but the BPD children used 
more bronchodilators. (Gross et al 1998)  
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5.  Tests of lung function in infancy and childhood 
 
Lung function can be assessed in infancy and childhood by measuring forced expiratory flow, 
lung volume, compliance and resistance, respiratory pattern, chest wall motion and gas 
mixing, as reviewed by the American Thoracic Society (ATS)/ European Respiratory Society 
(ERS) (1993), Sovijärvi et al (1994), Kotecha & Silverman (1999) and Sly et al (1999). 
 
Measures of forced expiratory flow 
Maximal expiratory flow (MEF) on the descending portion of the MEF-volume curve is 
independent of effort and reflects airway caliber peripheral to the segment subjected to flow 
limitation. The measurement of MEF is a standardized and sensitive test of abnormalities in 
the intrathoracic airways. Forced expiratory flow-volume relationship can be measured by the 
forced deflation technique in intubated infants and by the rapid thoracoabdominal impression 
method in non-intubated infants, and it can also be used with bronchodilating or 
bronchoconstricting agents. Near school age, the measurements become more accurate. 
Ventilatory capacity is influenced by lung volume, airway caliber, compliance and elasticity 
of the lungs and chest and respiratory muscle function. In flow-volume spirometry, forced 
expiratory volume in one second (FEV1) (or in 0.5 or 0.75 s) is the best indicator of 
ventilation capacity and represents mainly the larger airways, as does peak expiratory flow 
(PEF). Forced vital capacity (FVC) measures the dynamic volume of the lungs. Forced 
expiratory flow at 50% (FEF50) and during the middle half of FVC (FEF25-75) represent the 
airflow in medium-sized and small airways and the compliance of lung tissue as well. 
Spirometry is used to differentiate between obstructive and restrictive dysfunction and, 
combined with bronchodilators, bronchoconstrictors or exercise, to assess hyperreactivity. 
 
Measures of lung volume 
Functional residual capacity (FRC), i.e. the volume of air in the lungs and airways at end-
expiration, is a balance between the outward recoil of the chest wall and the inward recoil of 
the lungs. FRC is the only lung volume that can be measured accurately and repeatedly in 
infants, by the whole-body plethysmography or gas dilution techniques (helium dilution and 
nitrogen washout). In whole-body plethysmography, a child, placed on a rigid container, 
makes respiratory efforts against an occlusion at the airway opening. The changes in pressure 
at the airway are related to the changes in volume, and thoracic gas volume (TGV) can be 
calculated by applying Boyle´s law. Plethysmography measures all gas present in the thorax, 
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including that not in direct communication with the airway (gas trapping). In healthy infants, 
TGV measurements tend to be reproducible. The helium dilution technique is based on the 
principle of gas equilibration between an unknown lung volume and a known volume 
containing helium as an indicator gas. Gas mixing is produced by ventilatory movements, and 
assuming a mass balance, the unknown lung volume can be derived from the change in 
helium concentration. The nitrogen washout technique measures the volume of nitrogen 
washed out of the lungs when the infant rebreathes nitrogen-free gas. Gas dilution techniques 
may underestimate FRC with gas trapping due to airway obstruction. At preschool age, lung 
volumes, such as total lung capacity (TLC), residual volume (RV) and RV/TLC ratio, can be 
measured by whole-body plethysmography with the patient sitting in a cabine. The static lung 
volumes [vital capacity (VC), TLC, RV/TLC] can be estimated by the single-breath method 
of the pulmonary diffusing capacity, even if the presence of air trapping can underestimate 
TLC. 
 
Measures of compliance and resistance 
The intrinsic elastic properties of the lungs and the chest can be assessed by measuring 
compliance and resistance during maturation. Dynamic techniques, such as body 
plethysmography, forced oscillation and the interrupter technique, are applied during 
spontaneous breathing or mechanically assisted ventilation. Passive techniques, such as 
multiple occlusion, passive flow-volume and weighted spirometry, are done after silencing of 
the respiratory muscles. All require measurements of airflow, volume and pressure; 
transpulmonary pressure is approximated by measuring the difference between the airway and 
esophageal pressures. Compliance (C) is calculated as the quotient of the change in volume 
divided by the pressure applied. As it is proportional to changes in lung volume, specific 
compliance (corrected for FRC) can be used instead. Respiratory system resistance, i.e. the 
change in pressure divided by flow, is dominated by the upper airways, and the measured 
values hence do not reflect modest changes in lower airway pressure. Therefore, only 
relatively large changes in airway resistance (Raw) due to bronchodilators can be detected. At 
preschool age, plethysmographic measurements of Raw and specific conductance (SGaw) can 
be performed with the patient sitting in a cabin; Gaw is the reciprocal of Raw, and SGaw is 
related to volume [SGaw = 1/(Raw xTGV)]. 
   Forced oscillation technique (FOT) was introduced by DuBois et al in 1956 as a method to 
characterize respiratory impedance and its two components, resistance (Rrs) and reactance 
(Xrs), over a wide range of frequencies. Flow oscillations generated by a loudspeaker are 
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applied to the mouth and superimposed on normal breathing: FOT uses pseudorandom noise, 
and its user-friendly commercial modification, impulse oscillometry (IOS), uses rectangular 
pulse signals containing harmocis up to 35 Hz or higher (Vogel & Smidt 1994, Hellinckx et al 
2001). The output pressure and flow signals are analyzed for their amplitude and phase 
difference, to determine the Rrs and Xrs of the total respiratory system and even to study 
airway mechanics during quiet tidal breathing. The oscillometric method has been used to 
describe the mechanical properties of the lung in children with asthma, cystic fibrosis and 
chronic respiratory symptoms (Solymar et al 1984, Lebecque et al 1987, Lebecque & 
Stănescu 1997, Timonen et al 1997, Hellinckx et al 1998)  as early as the age of 2-4 years 
(König et al 1984, Duiverman et al 1985, Bisgaard & Klug 1995, Klug & Bisgaard 1996). 
Scant data are available on preterm children (Duiverman et al 1988). Recently, the values of 
IOS and FOT were shown to be similar, but not identical (Hellinckx et al 2001). 
 
Measures of gas exchange 
The function of the lung parenchyma can be assessed by measuring the pulmonary diffusing 
capacity, i.e. the diffusion of the inspired gas from the lungs into the circulation. At preschool 
or school age, a single-breath method, using an inhalation of a known mixture of an inert gas 
(helium) and a diffusing gas, can be used for the analysis of the total pulmonary diffusing 
capacity (DLCO) and the diffusing coefficient for carbon monoxide (KCO). (Salorinne 1994) 
 
6.  Lung function in children born prematurely 
 
Infancy 
During the neonatal intensive care, due to difficulties in performance and interpretation, 
measurements of lung function have been mostly done as part of trials of medication or 
ventilation techniques. More studies have been done on infants, but the interpretation of data 
is influenced by sedation, considerable short-term variability and normalization procedures, 
such as weight. Forced expiratory techniques have improved the accuracy of measurement 
and made it possible to define the degree of dysfunction, the responses to specific therapy and 
the onset of and recovery from respiratory problems. Both static and dynamic compliances are 
low during neonatal intensive care and largely influenced by the ventilation technique and the 
distending pressures applied. Compliance measurements have been used to investigate the 
effect of surfactant in neonates and the effect of glucocorticoids in young children with 
interstitial lung disease. Studies with bronchodilators have shown bronchoconstriction to 
   
 27
occur even in preterm infants during the first weeks of life. (ATS/ERS 1993, Kotecha & 
Silverman 1999) In infants, chest wall compliance is 3-fold compared to lung compliance, 
and it may be even higher in preterm infants (5-7-fold greater), making the respiratory pump 
less efficient in moving the tidal volume (Gerhardt & Bancalari 1980, ATS/ERS 1993). Raw 
values are high at birth but decrease rapidly during the first year of life. After birth, 
conductance increases much more slowly than FRC, resulting in a rapid drop of SGaw 
(Gerhardt et al 1987a). The age-specific changes in Raw can be only evaluated in relation to 
changes in lung volume, as by using SGaw. 
 
The survivors of old BPD in the 1960-1970´s had increased Raw, increased airway 
reactivity, increased FRC, high arterial carbon dioxide tension, low arterial oxygen tension, 
right or/and left ventricular hypertrophy and pulmonary and systemic hypertension in infancy 
(Northway et al 1990b). 
In VLBW children born before the surfactant era in the late 1970´s, TGV was higher, and 
dynamic compliance and pulmonary and airway conductance were lower at the age of six 
months and normalized by the end of the first year in those ventilated for RDS compared with 
non-RDS infants, regardless of whether or not normalized for body weight or TGV. The 
disturbances of lung function were particularly severe in infants with lower respiratory tract 
infection. (Wong et al 1982a) 
In VLBW infants born in the 1980´s, FRC was in the normal range, but compliance 
decreased and Raw increased after both intermittent mandatory ventilation and high-frequency 
oscillatory ventilation at two months of age (Gerhardt et al 1989). In larger preterm infants 
with RDS, pulmonary mechanics were almost similar during early infancy after surfactant or 
placebo treatment but, at the age of one year, total pulmonary resistance and the resistive 
work of breathing were lower and expiratory airflow higher in surfactant-treated individuals, 
suggesting decreased residual bronchopulmonary damage (Abbasi et al 1993). 
In BPD, the flow-volume curves of tidal breathing generated by the compression 
technique were clearly abnormal, exhibiting severe flow restrictions (Tepper et al 1986). 
Respiratory system compliance was low during the first months, returning to normal by 1-3 
years. Specific compliance was also low, indicating that other factors apart from lung volume 
were making the lung stiff. Resistance values were mostly high, indicating the severity of the 
disease. SGaw was low (60% of predicted) in infancy and increased only slightly (to 70%) 
during the first three years of life. FRC was reported to be low during the first six months of 
life, exceeding the normal by 12 months, measured as nitrogen washout. (Gerhardt et al 
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1987b) Plethysmographic lung volumes, which represent all gas present in the chest, tended to 
be higher, while FRC and the FRC/TGV ratio were lower in symptomatic than in 
asymptomatic infants, suggesting true hyperinflation, as shown in LBW infants at 12 months 
of age (Yuksel & Greenough 1991). 
 
School age 
The survivors of old BPD continued to have airway obstruction, bronchial hyperreactivity 
and hyperinflation in lung function studies at school age (Smyth et al 1981, Bader et al 1987) 
and even in adolescence (Northway et al 1990b). Catch-up improvement in abnormal lung 
function during the early school years was also reported (Blayney et al 1991). Of the original 
BPD group, 24% had fixed airway obstruction, and 52% had reactive airway disease in 
adolescence; the BPD children had a higher Raw and a lower SGaw than those with no BPD 
(Northway et al 1990b). Limited exercise tolerance, defined as reported symptoms or 
measured abnormal oxygen saturation, was seen (Bader et al 1987, Northway et al 1990b). 
DLCO was found to be normal (Smyth et al 1981) or slightly decreased (Northway et al 
1990b). The duration of both endotracheal intubation and mechanical ventilation associated 
significantly with values of lung function (RV/TLC, FRC). Lung injury in BPD was 
suggested to have a role in the pathogenesis of later pulmonary dysfunction, as the reduction 
of airway growth during the rapid postnatal phase of lung growth could contribute to 
disproportionate undergrowth of the airway lumen, resulting in increased airway resistance. 
(Northway et al 1990b) 
   
A cohort of LBW children born in the late 1970´s, irrespective of neonatal respiratory illness, 
were shown to have lower expiratory flow indices with well preserved VC than controls 
representing local school children. Airway function correlated strongly with birth weight and, 
to a lesser extent, with gestational age, maternal smoking, male sex and cough. The BPD 
subgroup also had reduced FVC. (Chan et al 1989b) Four-week inhalation of beclomethasone 
had no effect on symptoms or lung function in the 44% of the children who showed increased 
airway responsiveness in histamine challenge (Chan & Silverman 1993). A Finnish cohort 
study of children born very prematurely in the same period compared BPD, ventilated non-
BPD, non-ventilated and full-term control children. Despite few clinical problems at school 
age, the BPD children had markedly lower SGaw and larger RV than the term controls, 
explained by increased Raw, air trapping and reduced elasticity of the lungs. The non-
ventilated children did not differ from the controls. Contrary to the study of Chan et al, 
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neonatal oxygen treatment associated with more severely impaired SGaw, RV and FEV1. 
(Hakulinen et al 1990) VLBW children showed increased airway reactivity, irrespective of 
RDS, at 10-13 years of age, and DLCO was decreased in the non-RDS group (Galdès-Sebaldt 
et al 1989). Later studies showed that VLBW children had a significant change towards 
normal in FEV1 and RV in follow-up at 8-14 years. More improvement was seen in ELBW 
children, who still had significantly more impaired values reflecting airflow, but not lung 
volume and air trapping at age 14 years compared with term controls. Mechanical ventilation, 
oxygen supplementation and BPD at 28 days had no effect on changes over time, but asthma 
and exposure to smoking decreased the improvement. (Doyle et al 1999, Doyle 2000a) 
Nikolajev et al (2002) assessed the lung function of discordant twins with LBW. They 
showed that bronchial hyperreactivity was common in challenge tests at school age, but 
small-for-gestational-age (SGA) was not associated with major impairment in lung function. 
 
The increasing survival of more immature infants in the 1980´s focused the lung function 
studies on VLBW, and oxygen supplementation at 36 weeks was mainly used as a definition 
of BPD. These children had reduced values of airway flow, lower SGaw and lower DLCO than 
controls, with associations with birth weight, suggesting structural changes in lung tissue due 
to prematurity itself (Hakulinen et al 1996). BPD children had even more severely impaired 
expiratory flow values and were more responsive to histamine than non-BPD children, which 
was of clinical significance, as the latter finding associated significantly with respiratory 
symptoms (Pelkonen et al 1997). In another study, impaired lung function was confirmed in 
BPD, but not in non-BPD children born very prematurely, but their mean birth weight was 
higher than in the former studies (Gross et al 1998). After severe BPD with a need for home 
oxygen therapy, those with the most severely impaired expiratory flow had seriously 
decreased diffusing capacity at the age of 11 years. Pulmonary dysfunction correlated with the 
time of oxygen supplementation. Symptoms correlated with the reversible component of 
airway obstruction rather than the fixed component. (Jacob et al 1998) In children born with 
<800g of birth weight, low oxygen consumption in a treadmill test suggested a lower level of 
fitness. Even with such a low birth weight and without apparent pulmonary abnormalities, the 
children with BPD differed from the non-BPD group in the frequency of obstructive 
abnormalities in lung function. (Kilbride et al 2003) After an exogenous surfactant trial, 
spirometric parameters were better in children treated with surfactant compared to placebo, 
suggesting that even in small preterm infants, advances in initial intensive care can improve 
the pulmonary outcome (Pelkonen et al 1998). 
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7.  Other indices associated with lung disease 
 
Immune response 
In asthma, the degree of inflammation is associated with the severity of basic lung function 
impairment or the reactivity to bronchoconstrictors or exercise (Bousquet et al 1990, Venge 
1994). The soluble markers of allergic inflammation have been reviewed by Venge (1994) 
and the biopsy markers by Jeffery et al (2000b). Eosinophil-mediated damage of the 
respiratory epithelium emerged as a major pathogenetic mechanism in asthma (Bousquet et al 
1990), whereas COPD in adults involved a prominence of neutrophils (Lacoste et al 1993). 
Merritt et al (1981) found a prominence of neutrophils and evidence of inflammatory injury in 
the airways of newborn infants developing BPD. A secretion product of activated eosinophils, 
eosinophil cationic protein, was elevated in the serum of asthma patients (Venge 1994). 
Myeloperoxidase, secreted by activated neutrophils, was increased in bronchoalveolar lavage 
fluid in COPD (Lacoste et al 1993). Lymphocytes were shown to be important in the 
pathogenesis of both asthma (Robinson et al 1993, Azzawi et al 1990) and COPD 
(O´Shaughnessy et al 1997, De Jong et al 1997), CD4 T-lymphocytes predominating in 
asthma with eosinophils and CD8 T-lymphocytes in COPD with neutrophils and 
macrophages, as reviewed by Jeffery (2000a). 
 
Data on the inflammatory basis of lung function abnormalities at school age in children born 
very prematurely are sparse. Treatment of low birth weight children with inhaled 
glucocorticoids had no significant effect on baseline lung function or the airway response to 
histamine, arguing against an inflammatory basis of the airway hyperresponsiveness in these 
children (Chan & Silverman 1993).  However, schoolchildren born very preterm were shown 
to have a low CD4:CD8 lymphocyte ratio in peripheral blood in contrast to a normal 
CD4:CD8 ratio found in asthma, bronchial lability associated with specific T-cell subsets and 
elevated serum eosinophil cationic protein. The changes in lymphocyte subsets suggested the 
immunological abnormalities to be related to BPD. (Pelkonen et al 1999)   
 
Examination of induced sputum differential cell counts were a non-invasive method to 
evaluate airway inflammation (Pavord et al 1997), but it is not an ideal routine test for 
children, as it requires much work of skilled personnel and good cooperation of the patients. 
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Exhaled nitric oxide (eNO) 
Nitric oxide (NO) gas is produced by various cells within the respiratory tract from L-arginine 
in synthesis catalyzed by NO synthase (NOS) enzymes, as reviewed by Barnes & Belvisi 
(1993) and Morris & Billiar (1994). There are at least three NOS isoenzymes: NOS1 (nNOS 
or neuronal NOS), NOS2 (iNOS or inducible NOS) and NOS3 (eNOS or endothelial NOS) 
(Yates et al 1995). All of the three isoenzymes have been detected in fetal lung and are 
individually regulated (Sherman et al 1999, Aikio et al 2002). NO derived from constitutive 
NOS (NOS1 and NOS3) is involved in the physiological regulation of airway function, 
whereas NO derived from inducible NOS (in macrophages, endothelial, smooth muscle and 
epithelial cells, fibroblasts and neutrophils) has an important role in respiratory inflammatory 
reactions and host defence. NO is a potent vasodilator of bronchial circulation, a regulator of 
pulmonary circulation and an important neurotransmitter in the neural bronchodilator system. 
   
In 1991, Gustafsson et al first described NO in the exhaled air (eNO) of guinea pigs, rabbits 
and human. Soon thereafter, elevated levels of eNO were reported in asthma patients (Alving 
et al 1993, Kharitonov et al 1994, Persson et al 1994). The cellular origin of eNO was still 
unclear. High concentrations were detected in the nasal air of normal subjects (Alving et al 
1993), but when nasal contamination was prevented by expiration against resistance, eNO 
was shown to originate from the lower respiratory tract (Kharitonov et al 1997). Oral 
glucocorticoids reduced eNO in asthmatic patients, but not in healthy subjects (Yates et al 
1995, Baraldi et al 1997). In patients with atopic asthma, inhaled glucocorticoids decreased 
eNO (Kharitonov et at 1996), but did not prevent the increase in acute exacerbations in 
children (Baraldi et al 1997). Viral respiratory infections raised (Kharitonov et al 1997) and 
smoking reduced eNO (Persson et al 1994). In chronic obstructive disease (COPD), normal or 
low eNO values were measured during the stable phase, but elevated levels might serve in 
monitoring disease activity (Maziak et al 1998). In cystic fibrosis, low nasal and normal 
exhaled NO values were reported (Lundberg et al 1996, Balfour-Lynn et al 1996). In a recent 
study, eNO was superior to baseline lung function and bronchial responsiveness in identifying 
preschool children with asthma (Malmberg et al 2003). 
Infants with acute wheezy bronchitis had low eNO levels, while premature infants without 
respiratory disease did not differ from term infants (Ratjen et al 2000). In ventilated preterm 
infants, bronchoalveolar lavage fluid nitrate was similar in BPD, RDS and control children 
during the first week of life, but remained high in those who later developed BPD (Vyas et al 
1999). ENO levels were high during the second day in ventilated preterm infants. Despite the 
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absence of any significant association with the respiratory variables, the infants with the 
highest levels manifested most severe BPD (Aikio et al 2002). Recently, high eNO 
concentrations were related to BPD in face mask measurements at term (Leipälä et al 2004). 
 
In evaluating the degree of airway inflammation in asthmatic children, eNO concentration and 
sputum eosinophil counts were concordant. Thus, eNO was proposed as an easy-to-measure 
marker of eosinophilic airway inflammation. (Piacentini et al 1999, Mattes et al 1999) 
 
8. Follow-up of growth, neurodevelopment and cardiac function in children born 
prematurely 
 
Growth 
In BPD children born in 1970-1980´s, growth retardation was common in early observations 
at three years (Northway 1979) and in a follow-up at two years of age (Markestad & 
Fitzhardinge 1981); in the latter study, it associated with severe and prolonged respiratory 
dysfunction. In adolescence or early adulthood, those with BPD were significantly shorter and 
weighed less than non-BPD individuals or term controls (Northway et al 1990b). Others found 
no impairment of growth in severe BPD at the age of 10 (Bader et al 1987).  
At school age, heights in relation to age among 20 children with BPD at 28 days were 
significantly lower than those of term controls, and weights adjusted for height were also 
lower. The non-BPD children did not differ from term controls. (Hakulinen et al 1996) The 
children with BPD at 36 gestational weeks were shorter for age than those with no BPD or 
controls (Pelkonen et al 1997). In a cohort study, VLBW children were shorter and lighter 
and had smaller head circumferences at 14 years than those with normal birth weight, with 
catch-up growth at 8-14 years. There were no differences in the stage of puberty. (Ford et al 
2000) In that study, the ELBW girls were 4.5 cm and the ELBW boys 5.8 cm shorter at 14 
years than the controls (Doyle 2000a), but no similar difference was detected at age 11 by 
others (Kilbride et al 2003). In a 20-year follow up of VLBW children, boys were shorter and 
lighter than controls at eight years, whereas girls were only lighter. Catch-up growth in 
weight, height and body mass index occurred during 8-20 years of age among females; the 
males remained smaller at 20 years, especially those who were SGA. (Hack et al 2003)  
 
In the 1990´s, Barker presented a hypothesis of the fetal origin of coronary heart disease 
(1995), and further studies consistently supported this finding of an association between low 
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birth weight, especially thinness at birth, catch-up growth in childhood and coronary disease 
in adulthood (Forsén et al 1999). In a follow-up of growth, most VLBW infants born in the 
surfactant era had not achieved the median birth weight of a fetus at the same gestational age 
on hospital discharge. Appropriate-for-gestational-age infants, who did not develop BPD, 
IVH, NEC or late sepsis, gained weight faster. (Ehrenkranz et al 1999) In a prospective study 
of longitudinal growth, infants born at <29 gestational weeks had an initial period of poor 
growth and a catch-up period at 4-5 years and mainly achieved normal weight and height by 
seven years (Niklasson et al 2003).    
 
Neurosensory development  
Among the survivors of the original BPD group, grade repetition at school and abnormalities 
in coordination, gait and muscle tone were reported; five out of 26 had CP, three  had hearing 
loss and one ROP compared with none of the controls (Northway 1990a). In a follow-up of 26 
infants with BPD, 25% had low Bayley scores (<85) at 18 months, related to perinatal and 
neonatal events rather than BPD (Markestad & Fitzhardinge 1981). In a population-based 
Swedish follow-up cohort, the live birth prevalence of CP, especially spastic diplegia, 
increased during the 1970-1980´s, reflecting the improved survival of VLBW infants 
(Hagberg et al 1989). Later, no further increase was seen, but a slight decrease in preterm CP. 
In 1991-1994, the prevalence was 81 per 1000 for infants of 1000-1499 g birth weight. 
(Hagberg et al 2001) IVH and PVL were powerful predictors of CP (Hagberg et al 1996, 
Salokorpi et al 1999). Despite the improved survival of more immature infants, the overall 
incidences of CP and IVH have not increased. However, the risk of abnormal neurological 
outcome increases sharply with decreasing birth weight. In a multicenter study (1995-1996), 
30% of VLBW infants with brain ultrasound examinations (89%) had IVH, 11% had grade 3-
4 and 26% of the infants with 501-750 g birth weight had severe IVH. Cystic PVL was noted 
in 5%. (Lemons et al 2001)   
 
Besides IVH and CP, VLBW infants have an increased risk for other neurosensory 
impairments, as reviewed recently by Tommiska [2003 (ELBW) and 2004a]. The families of 
BPD children reported more need for physiotherapy and occupational therapy and more 
concern for the child and impact of the child´s health on family life compared to non-BPD 
children (Korhonen et al 1999a). At age 11, ELBW children were judged as occasionally 
active or inactive by their parents, which differed from controls (Kilbride et al 2003).  
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Cardiac function 
The severe old BPD was frequently accompanied by right ventricular hypertrophy and 
cardiomegaly with cor pulmonale in electrocardiogram (Northway et al 1967, Markestad & 
Fitzhardinge 1981, Northway 1990a) and by elevated right ventricular end-diastolic volume 
and increased right ventricular wall thickness in echocardiography as late as school age 
(Smyth et al 1981). After severe BPD with a need for home oxygen therapy, recurrent 
episodes of heart failure were found in the children with most severely impaired lung function 
(Jacob et al 1998). Pulmonary hypertension with increased pulmonary vascular resistance and 
intrapulmonary shunting was demonstrated at cardiac catheterisation in children with severe 
BPD at 3 months - 5 years of age associated with poor prognosis (Abman et al 1985, Berman 
et al 1986, Bush et al 1990). 
Pulmonary arterial pressure (PAP) can be assessed non-invasively by Doppler 
echocardiography by measuring tricuspid valve regurgitation or pulmonary flow indices. PAP 
is inversely related to the ratio between acceleration time (AT) and right ventricular ejection 
time (RVET) (Kosturakis et al 1984). The VLBW children with BPD at 28 days born in the 
late 1980´s had a slower drop in PAP than those without BPD, followed by an increase during 
14-28 days of age (Gill & Weindling 1993). Furthermore, the children with BPD had lower 
Doppler-mode-derived variables of pulmonary flow (AT, AT/RVET, pulmonary flow 
velocity) at two years of age than those without BPD. The children with clinically severe BPD 
and the most severe peripheral airway obstruction had the shortest acceleration time. (Farstad 
et al 1995) In infants with RDS born in the 1990´s, the initially raised PAP remained 
persistently elevated in a one-year follow-up in those who developed BPD. PAP was 
inversely related to gestational age and corrected age at examination in preterm born infants 
and to the duration of supplemental oxygen administration in infants with BPD. (Subhedar & 
Shaw 2000) Previously, early findings of pulmonary hypertension were independently 
associated with BPD at 36 weeks and suggested to be a sensitive marker of pulmonary injury 
(Subhedar et al 1998). The cardiac findings in BPD have been recently reviewed by 
Korhonen (2004a). 
 
In children born in the late 1980´s or early 1990´s, no cardiac hypertrophy (Farstad et al 1995, 
Korhonen et al 2004b) or significant pulmonary hypertension was seen at 2-7 years of age 
(Korhonen et al 2004b). 
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9.  Pharmacologic effects of glucocorticoids 
 
Synthetic glucocorticoids, DEX and betamethasone, have a greater affinity for glucocorticoid 
receptor than cortisol (7.1- and 5.4-fold higher, respectively), which additionally possesses 
mineralocorticoid activity (Ballard & Ballard 1995, Jobe & Bancalari 2001). 
 
Effects on the pulmonary defence systems 
The initial studies in lambs suggested a response of the surfactant system to antenatal 
glucocorticoids (Liggins 1969). Thereafter, all known components of surfactant have been 
induced by treatment with glucocorticoids, presumably resulting in an increased content of 
surfactant of normal composition and function, the effects depending on dosage and the stage 
of lung development (Ballard & Ballard 1995, Vyas & Kotecha 1997). In the original 
perinatal trial of our study population, after antenatal DEX, the requirements for surfactant 
treatment were lower (Kari et al 1994), but no significant differences were seen in tracheal 
fluid phosphatidylcholine despite the lesser need for ventilatory support (Kari et al 1995). 
Another study showed an increase in surfactant proteins after postnatal glucocorticoid, 
associated with improved initial lung function (Wang et al 1996).  
In animals, glucocorticoids cause precocious increases in the activity of the antioxidant 
enzymes superoxide dismutase, glutathione peroxidase and catalase. They regulate a 
relatively small subset of proteins in lung cells, which act as important mediators of hormonal 
effects. They induce both sodium-potassium-APTase and a subunit of the sodium channel 
involved in the clearance of lung fluid from airspaces. (Ballard & Ballard 1995) Recently, in 
preterm infants, the expression of epithelial sodium channel subunits was low but it was 
increased by therapeutic doses of glucocorticoids (Helve et al 2004). 
Glucocorticoids are among the most potent anti-inflammatory agents, but their role in lung 
inflammation is poorly understood. DEX treatment has been shown to decrease nearly all 
studied inflammatory indicators (Groneck & Speer 1995). In ventilated infants with BPD 
(Yoder et al 1991) or RDS (Wang et al 1997), neutrophils and other anti-inflammatory 
mediators were reduced in tracheal fluid, associated with improved pulmonary function, and 
recently, early in RDS, downregulation of polymorphonuclear leukocytes and monocyte 
activation was seen (Nupponen et al 2002). In rats, antenatal DEX has been shown to enhance 
the abundance of endothelial NOS protein expression in lungs at birth (Lin et al 2001). 
Recently, in ventilator-dependent infants, high eNO levels were shown to decrease after DEX 
treatment (Williams et al 2004). 
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Effects on lung structure and growth 
In animal studies, glucocorticoid treatment decreased the number of alveoli, which appeared 
larger and more mature with reduced septal mesenchyme (Vyas & Kotecha 1997). In rats, 
changes in the capillaries within the septa impaired the future formation of further alveoli 
(Tschanz et al 1995, Tschanz et al 2003). Low-dose long-lasting postnatal DEX therapy 
resulted in larger and fewer alveoli with reduced septal mesenchyme, leading to an 
emphysematous condition, but a high-dose short-term treatment accelerated lung maturation, 
followed by a step-back after discontinuation, with almost complete recovery, indicating that 
both dosage and duration might be critical in terms of lung response (Tschanz et al 2003). 
After antenatal glucocorticoids, the small but mature rat lungs at birth showed a growth 
rebound and normal later development (Adamson & King 1988); others reported impaired 
postnatal lung growth (Okajima et al 2001).  
Retinoids are essential developmental mediators, and particularly all-trans retinoic acid 
plays a key role in promoting septation. In neonatal rats, it also reversed the glucocorticoid-
induced inhibition of septation. (Massaro & Massaro 2000) 
In sheep, single or repetitive maternal, but not fetal, betamethasone treatment caused 
growth retardation persisting to term. Fetal treatment also improved lung function less, 
suggesting that maternal glucocorticoids induce factors participating in lung maturation. 
Repetitive treatment improved lung function more effectively than single treatment, but 
concerns arose about decreased growth and neurodevelopment. (Jobe et al 1998) A review of 
animal studies suggested that multiple courses of antenatal glucocorticoids improve lung 
function, but decrease birth and lung weight and restrict brain growth (Aghajafari et al 2002a). 
Scant data exist on human lung growth, mainly derived from lung function tests: no adverse 
effect of antenatal DEX was seen in VLBW infants with little or no neonatal lung disease 
during the first year of life (Wong et al 1982b). 
 
Effects on other tissues 
Glucocorticoids stimulate cytodifferentiation and cause precocious changes in different 
tissues, accelerating the rate of differentiation without altering the sequence of developmental 
events. They take part in glycogen metabolism, bile canaliculus formation, hematopoesis, 
enzyme induction, intestinal maturation and ion exchange in kidneys and enhance the insulin 
response to glucose and the adrenocorticotrophic hormone (ACTH) responsiveness of the 
adrenal cortex, resulting in maturation of the catecholamine responses to birth in preterm 
animals. The increased activity of myocardial adenylyl cyclase accounts for the improved 
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respiratory, cardiovascular and metabolic responses seen after treatment. (Ballard & Ballard 
1995) The modulating effects on tissue differentiation involve interactions with other fetal 
hormones, i.e. prolactin, thyroid hormones and catecholamines, insulin, EGF, interferon-γ and 
testosterone. In humans, antenatal therapy with glucocorticoid and thyrotropin-releasing 
hormone did not affect the incidence of RDS or BPD more than corticosteroid alone (Ballard 
et al 1998), despite previous results (Ballard & Ballard 1995). Antenatal DEX decreased 
plasma catecholamines, attenuating the birth-related increase (Kallio et al 1998, Banks et al 
1999); others reported normal responses in tests stimulating human corticotrophin release at 
one and two weeks after >8 courses and mild suppression in only some (Ng et al 1999). In 
sheep, antenatal low-dose DEX suppressed the pituitary-adrenal function but augmented the 
glycemic response to hypoxia (Fletcher et al 2000). 
In human, concentrations of amniotic fluid cortisol and corticoid conjugates, primarily 
derived from fetal cortisol, increase several-fold during the third trimester. Many infants with 
RDS begin their recovery 48-72 hours after birth, which timing is consistent with the 
accelerated production of surfactant in response to the elevation of cortisol that occurs in this 
disease.  Postnatal administration of hydrocortisone to infants with RDS did not improve their 
clinical course, suggesting the postnatal elevation in endogenous levels to be sufficient to 
induce lung maturity (Baden et al 1972). Thus, antenatal steroid is believed to mimic the 
intrauterine and postnatal exposure to endogenous glucocorticoid (Ballard & Ballard 1995). 
Very preterm infants may lack the capacity to produce enough cortisol to respond to 
extrauterine stress, and infants who develop BPD were seen to have low cortisol levels and a 
decreased response to ACTH after birth (Watterberg & Scott 1995). Low-dose hydrocortisone 
increased survival without BPD in ELBW infants, when instituted shortly after birth, 
particularly in those with chorioamnionitis (Watterberg  et al 1999).  
 
Brain development 
Despite differences in the timing of the peak brain growth, the general sequence is similar in 
animals and humans. Animal experiments have provided ample evidence of corticosteroid-
induced decrease in brain growth and abnormal development of the immature brain, but 
depending on dosage and timing, glucocorticoids may either enhance or reduce brain injury 
after a hypoxic insult  (Huang et al 1999, Whitelaw & Thoresen 2000, Aghajafari et al 2002a). 
In general, neurones in the human brain have stopped dividing by the third trimester, but 
those in the dentate gyrus continue to divide long after full term and are thus vulnerable to 
adverse influences. Despite the small molecular difference between betamethasone and 
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dexamethasone, their biological effects may differ. Among mice followed up into adulthood, 
the antenatally betamethasone-treated group showed enhancement of memory compared with 
the placebo group, whereas DEX treatment resulted in a decrement. (Rayburn et al 1997) 
 
10.  Trials on glucocorticoids during the antenatal - neonatal period 
 
10.1.  Glucocorticoid treatment of preterm infants 
 
After initial discouraging attempts to prevent BPD in children with RDS by using 
hydrocortisone (Baden et al 1972), DEX was adopted into use to facilitate the weaning of 
VLBW infants from the ventilator (Mammel et al 1983, Avery et al 1985, Harkavy et al 
1989, Kazzi et al 1990, Ohlsson et al 1992). The usual initial dose of DEX was 0.5 mg/kg/d 
administered for 2-42 days with a different tapering schedule. In most studies, open steroids 
were allowed afterwards. In a small study, a 42-day course at two weeks of age in infants 
dependent on supplemental oxygen and mechanical ventilation was superior to an 18-day 
course or placebo with respect to the pulmonary and neurodevelopmental outcome 
(Cummings et al 1989). One study on oxygen-dependent infants at four weeks of age showed 
more rapid improvement of ventilation in the DEX group, but no difference in the duration of 
oxygen supplementation; new periventricular abnormalities on brain ultrasound scans were 
reported (Noble-Jamieson et al 1989). A multicentre international trial, organized by 
Collaborative Dexamethasone Trial Group (CDTG) (1991), studied the effect of 7-day 
treatment on chronic oxygen dependency at three weeks of age in 287 VLBW infants born in 
1986-1989. In the DEX group, the duration of further assisted ventilation was reduced, and 
the infants with no mechanical ventilation at entry tended to need oxygen supplementation for 
a shorter time. Hypertension and hyperglycemia were encountered. The Finnish study, in 
which our study children participated, aimed to prevent BPD in infants dependent on 
mechanical ventilation by earlier treatment at ten days of age. A shorter duration of 
supplemental oxygen in DEX-treated girls, but not in all infants, and short-lived suppression 
of basal cortisol were reported.  Infants requiring ventilator at the age of ten days were at high 
risk of developing BPD, as evaluated at the age of four weeks, and were thus not treated early 
enough for the treatment to be truly prophylactic. (Kari et al 1993)  
Apart from chronic oxygen dependency, with growing evidence of the inflammatory basis 
of BPD (Yoder et al 1991, Groneck & Speer 1995), DEX was increasingly given soon after 
birth to infants on mechanical ventilation for severe RDS. Pulmonary mechanics had already 
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been shown to improve and extubation by two weeks of age to increase among infants treated 
within 12 hours after birth in an early study before the surfactant era (Yeh et al 1990). In an 
Israeli multicentre trial of 248 preterm infants on mechanical ventilation with more than 40% 
oxygen for RDS, treated with rescue surfactant, early postnatal DEX did not reduce the 
incidence of BPD at either 28 days or 36 gestational weeks of age. The lesser need for 
mechanical ventilation at the age of three days was not sustained at seven days of age. 
Gastrointestinal hemorrhage associated with DEX. (Shinwell et al 1996) However, 43 VLBW 
infants on mechanical ventilation showed significant improvement in respiratory compliance 
and tidal volume, with further increase until seven days of age: the fraction of inspiratory 
oxygen (FiO2) was reduced, weaning was facilitated, and there was less BPD at 36 weeks 
(DEX 10%, placebo 47%). As the decreasing beneficial effect of surfactant increases the 
susceptibility to barotrauma in the second week of life, the initiation of glucocorticoids during 
this time could have minimized the lung injury and thus explained these results. (Durand et al 
1995) 
The initial goal was to rescue severely ill VLBW infants from prolonged mechanical 
ventilation and to prevent BPD. With the increasing use in less severe disease or as 
prophylaxis, there was growing concern of the long-term sequelae. Ng (1993) reviewed ten 
postnatal DEX trials: hyperglycemia, hypertension, adrenal suppression and growth 
impairment were common but usually reversible. Gastrointestinal bleeding, pulmonary air 
leak, osteopenia, bone fracture, immunosuppressive effects and hypertrophic cardiomyopathy 
were seen. Although no major neurodevelopmental risk was found in studies of antenatal 
DEX, attention was raised to identify all treatable causes preventing successful weaning 
before starting steroid treatment, such as anemia, PDA and sepsis.   
 
Bhuta & Ohlsson (1998) reviewed ten studies of postnatal DEX treatment before 14 days of 
life. The risk of BPD at 28 days or 36 gestational weeks was significantly reduced, especially 
in infants treated at 7-14 days of age, in whom mortality was reduced as well. In this group, 
only three children would need to be treated to prevent one infant from developing BPD. 
More recent meta-analyses reviewed separately trials in which glucocorticoid, usually DEX, 
was started either early (<96 hours), moderately early (7-14 days) or delayed (>3 weeks) after 
birth (Halliday & Ehrenkranz 2000a, 2000b, 2000c).  
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Early postnatal glucocorticoid treatment  
A meta-analysis of early postnatal corticosteroids for preventing BPD covered the following 
studies: Baden et al 1972 (hydrocortisone), Yeh et al 1990, Sanders et al 1994, Shinwell et al 
1996, Rastogi et al 1996, Suske et al 1996, Subhedar et al 1998, Wang et al 1997, Yeh et al 
1997, Mukhopadhyay et al 1998, Tapia et al 1998, Garland et al 1999, Kopelman et al 1999, 
Lin et al 1999, Romagnoli et al 1999, Soll et al 1999, Stark et al 1999, Watterberg et al 1999 
(hydrocortisone) and Sinkin et al 2000 (Halliday & Ehrenkranz 2000a). Surfactant use was 
common in most studies. DEX treatment did not reduce mortality, but facilitated weaning and 
reduced the risk of PDA and pulmonary air leaks. Death or BPD and BPD at 28 days or 36 
weeks were decreased, and the recipients of DEX required less steroids during the later 
respiratory course. The risks of hyperglycemia, hypertension and growth failure, 
gastrointestinal bleeding, intestinal perforation and hypertrophic cardiomyopathy were 
increased, but no increase of NEC, infection or pulmonary hemorrhage was detectable. The 
risk of severe IVH, PVL or severe or any ROP was not affected, either. The infants who 
underwent cranial ultrasound scans showed a borderline increase in the risk of PVL (Soll et al 
1999). In one study of a 3-day course in surfactant-treated RDS infants with a high risk for 
BPD, IVH of any grade was more common in the placebo group (Garland et al 1999). Two 
studies presented neurological follow-up data with increased risks of abnormal neurological 
examination, developmental delay, CP and death or CP (Yeh et al 1998, Shinwell et al 2000). 
A pilot study of low-dose hydrocortisone for 12 days in 40 ELBW infants revealed increased 
survival without BPD at 36 weeks and reductions in the duration of oxygen supplementation 
and mechanical ventilation with no detectable difference in side effects (Watterberg et al 
1999). 
In a recent study, early postnatal DEX was given as a 3-day course at a lower dose of 0.15 
mg/kg/d, followed by 7-day tapering, to 220 ELBW infants on mechanical ventilation. The 
risks of death and BPD at 36 weeks did not differ, but the DEX-treated infants were less 
likely to receive supplemental oxygen at 28 days and open DEX later. Spontaneous 
gastrointestinal perforation, especially with indomethacin use, was more common in the DEX 
group, as were lower weight and smaller head circumference at 36 gestational weeks. (Stark 
et al 2001) 
 
Moderately early postnatal glucocorticoid treatment 
A meta-analysis of moderately early postnatal corticosteroids for preventing BPD included 
the following studies: Cummings et al 1989, Kari et al 1993, Brozanski et al 1995, Durand et 
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al 1995, Kovacs et al 1998, Papile et al 1998 and Romagnoli et al 1998 (Halliday & 
Ehrenkranz 2000b). DEX treatment reduced mortality at 28 days, death or BPD and BPD at 
28 days or 36 weeks and the need for later steroids and facilitated extubation, but had no 
effect on the risk of pneumothorax or NEC. Adverse effects included hyperglycemia, 
hypertension, gastrointestinal bleeding, hypertrophic cardiomyopathy, adrenal suppression 
(Kari et al 1993) and infection. One study showed significant differences in pulmonary 
mechanics and oxygen need at two days after DEX treatment with less BPD at 36 weeks 
(Durand et al 1995). In a study of 3-day treatment followed by 18 days of nebulized 
budesonide, the steroid group required less ventilatory support and supplemental oxygen at 
the second week of age and had better pulmonary compliance at ten days, but the 
improvements were not maintained, and the incidence of BPD at 36 weeks was not decreased 
(Kovács et al 1998). There was no effect on the incidence of severe IVH or severe ROP, but 
one study presented, apart from diminished weight gain, slowing down of head growth during 
DEX treatment in both 2-week and 4-week groups (Papile et al 1998). Only one long-term 
follow-up was available, with no increase in adverse neurological outcome (Cummings et al 
1989). 
 
Delayed postnatal glucocorticoid treatment  
A meta-analysis of delayed postnatal corticosteroids for chronic lung disease included the 
following studies: Ariagno et al 1987, Avery et al 1985, Harkavy et al 1989, Noble-Jamieson 
et al 1989, Kazzi et al 1990, CDTG 1991, Ohlsson et al 1992, Vincer et al 1998 and Kothadia 
et al 1999 (Halliday & Ehrenkranz 2000c). Surfactant was not used in most of the studies. 
DEX treatment improved respiratory compliance, facilitated extubation and reduced the need 
for oxygen supplementation and later steroids, but had no effect on survival or the duration of 
hospitalization. Only one study reported the incidence of BPD at 36 weeks to be decreased 
with borderline significance and death or BPD at 36 weeks to be decreased (Kothadia et al 
1999). Poor weight gain was seen in the DEX group, but no increase in the risk of infection, 
NEC or gastrointestinal bleeding. Abnormal neurological findings were increased in the 
DEX-treated children, but moderate to severe neurological impairment was not, either overall 
or in survivors. The increased risk of CP in survivors was of borderline significance, but in 
keeping with the findings of early postnatal treatment. No increase in blindness was detected. 
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Neurodevelopmental outcome after postnatal dexamethasone treatment 
A non-significant increase in cranial ultrasound abnormalities was reported after DEX 
treatment (Noble-Jamieson et al 1989, O´Shea et al 1999, Shinwell et al 2000), and an early 
trial of ELBW infants was discontinued because of adverse outcome, particularly PVL (Soll 
et al 1999, the Vermont Oxford Network Steroid Study Group 2001). On the contrary, one 
study reported more IVH in the placebo group (Garland et al 1999). In a study of ELBW 
infants, postnatal but not antenatal DEX exposure was associated with abnormal brain 
ultrasound findings and worse neurodevelopmental outcome at 18 months (LeFlore et al 
2002). Poorer head growth was detected at the age of 30 days in infants treated moderately 
early with 14-day DEX, compared to a 7-day early course (Romagnoli et al 1999). Later, even 
an early 3-day course at a lower dose of 0.15 mg/kg/d associated with a smaller head 
circumference at 36 weeks of gestational age in ELBW infants (Stark et al 2001). 
 
Follow-up studies of randomized trials have been few in number. In the trial of Cummings et 
al (1989), less abnormal neurodevelopmental outcomes (abnormal examination or Bayley 
developmental index) were seen at 15 months of age after a 42-day course at two weeks (2 
infants out of 9) compared to a 18-day course (7 out of 9) or placebo (3 out of 5), but another 
small study of a 12-day course failed to reveal any difference in Bayley scores at two years of 
age (Bhuta & Ohlsson 1998). 
In the follow-up of 209 children oxygen-dependent at three weeks in the CDTG trial 
(1991), no clear difference was evident at the age of three years in CP (20% vs 17%) or any 
other neurological disability after a 7-day course, but less hearing loss was suggested in the 
DEX group. Their disability score was described in our methods. Altogether 19% of the 
infants had CP, 8% had visual loss, and 16% suffered from hearing loss; 19% were classified 
as severely disabled and 35% as severely or moderately disabled; 18% were expected to need 
special school education and 13% extra help at school. The need for physiotherapy (42%), 
speech therapy (32%), occupational therapy (16%) and special schooling was common, but 
similar in both groups. Underestimation of disability was suggested to be due to the methods 
used. Neurological impairment was more common in the subgroup dependent on a ventilator 
at recruitment than those on oxygen only. (Jones et al 1995) 
In another trial of 118 infants, a 42-day course at 15-25 days of age increased the risk of 
CP (DEX 25% vs placebo 7%) and abnormal neurological examinations, such as hypotonia or 
possible or definite CP (45% vs 16%) at one year of age. Of the DEX-treated infants with CP, 
44% had normal neonatal brain ultrasound scans. (Kothadia et al 1999, O´Shea et al 1999) 
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Similarly, in two trials of early DEX, a 3-day course increased the incidence of CP (49% 
vs 15%), particularly spastic diplegia (28% vs 6%), and developmental delay (55% vs 29%) at 
2-6 years of age (Shinwell et al 1996, Shinwell et al 2000), and a 4-week course increased 
neurological abnormality, especially diplegia and hypotonia, at two years (40% vs 17%) (Yeh 
et al 1997, Yeh et al 1998). In the study of Shinwell et al, all infants with PVL, 38% of IVH 
grade 1-2 and 53% of IVH grade 3-4 developed CP; 22% of the children with CP had normal 
neonatal ultrasound scans, all treated with DEX. In the study of Yeh et al, more fast activity 
in electroencephalograms (EEG) was seen in the DEX group, with no correlation with the 
outcome, but the overall abnormalities in EEG, brain stem auditory evoked potential and 
visual evoked potential did not differ between the groups. The incidence of CP was twofold in 
children treated with DEX compared to those with placebo. No difference was seen in either 
visual (Yeh et al 1998, Shinwell et al 2000) or hearing problems (Shinwell et al 2000). 
The differences in neurological outcome were not confirmed in a recent small follow-up 
study at three years (Romagnoli et al 2002). 
 
Barrington (2001) reviewed eight randomized controlled trials with neurodevelopmental 
follow-up data of 679 survivors out of 1052 participants. According to the meta-analysis, 
postnatal glucocorticoid was associated with an increase in CP and neurodevelopmental 
impairment. The studies with less than 30% contamination with open steroid later showed a 
greater steroid effect, and the relative risk of CP was 2.86 (95% confidence interval: 1.95-
4.19). The conclusion was to abandon the use of steroids for this indication in the absence of 
evidence of any long-term benefits. 
 
Growth after postnatal dexamethasone treatment 
Poor growth and weight gain are common findings associated with DEX, but usually 
reversible (Ng 1993, Halliday & Ehrenkranz 2000ac). Diminished weight gain was shown 
during 2-week and 4-week courses (Papile et al 1998) and after a 2-week moderately early 
and a one-week early course, but catch-up occurred soon (Romagnoli et al 1999). A recent 
study of ELBW infants reported a significantly lower weight even after a low dose (Stark et al 
2001). 
In the follow-up of the CDTG trial (1991), no statistical differences emerged in growth at 
the age of three years after 7-day postnatal treatment with DEX or placebo. Height, weight 
and head circumference were below the average in both groups. (Jones et al 1995) After early 
treatment, in a study of a 4-week course, which initially decreased the high need for oxygen, 
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somatic growth did not differ at two years of age in girls, but the DEX-treated boys were 
shorter and weighed less than the controls (Yeh et al 1998), while a 7-day course had no 
effect on growth at three years of age (Romagnoli et al 2002). 
 
Respiratory morbidity and lung function after postnatal dexamethasone treatment 
The short-term benefits of DEX to respiratory morbidity are evident and have been described 
previously. The initial improvement of pulmonary mechanics (Yeh et al 1990, Durand et al 
1995) was concomitant with the acute suppression of pulmonary inflammation (Yoder et al 
1991), but resulted in only a modest decrease in the incidence of BPD at 36 gestational weeks. 
In the follow-up of the CDTG trial (1991), despite improved weaning from the ventilator, 
no beneficial or adverse effects of a 7-day course on respiratory morbidity were evident at the 
age of three years. In all, based on questionnaires, 38% had frequent episodes of coughing or 
wheezing on exercise, at night or with common cold, and 48% had had at least one admission 
to hospital. In the DEX group, consultations for respiratory problems were more common and 
an excess of cot deaths were reported, even though late mortality was similar in both groups. 
(Jones et al 1995) However, a 4-week course of early DEX, which decreased the initially high 
need for oxygen and the incidence of PDA, associated with a lower incidence of upper 
respiratory infections and rehospitalization for respiratory reasons at the age of two years 
(Yeh et al 1998); frequent rehospitalizations until the age of one year were also less common 
after a delayed 42-day course (O´Shea et al 1999). The follow-up studies of randomized trials 
did not assess lung function after treatment. 
 
Cardiovascular findings after postnatal dexamethasone treatment 
Hypertension, as a common finding, and cardiomyopathy or myocardial hypertrophy were 
encountered after DEX treatment, but were usually reversible (Werner et al 1992, Ng 1993, 
Evans 1994, Yeh et al 1997). However, DEX-induced fatal cardiomyopathy has been reported 
(Riede et al 2001). 
In the cardiac follow-ups during randomized trials of a 42-day (Kothadia et al 1999) and a 
7-day course (Romagnoli et al 1999), DEX-associated ventricular septal hypertrophy and left 
ventricular ourflow obstruction were usually reversible within one month, but had clinical 
significance in some infants (Bensky et al 1996, Zecca et al 2001). Long-term follow-up has 
not been reported. 
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Recommendations and practice of postnatal dexamethasone treatment 
Despite the short-term benefits seen in infants treated moderately early, due to the initial 
findings on neurological outcome, early postnatal treatment is not indicated as a treatment of 
respiratory failure. Corticosteroids have been suggested to be reserved for infants not weaning 
from mechanical ventilation and studies made on lower doses, other steroids, alternative 
routes and late outcomes among survivors of randomized trials. (Halliday & Ehrenkranz 
2000abc) Others proposed to abandon the use of steroids for this indication, as no evidence of 
long-term benefits exists. In 2002, The American Academy of Pediatrics published guidelines 
for the use of postnatal steroid treatment and stated that it should not be routine and should be 
limited to exceptional clinical circumstances, such as infants on maximal ventilatory and 
oxygen support. The publication of concerns reduced the use of postnatal DEX: in Israel, 22% 
of infants were treated with open DEX after the age of seven days in 1994, compared with 6% 
of similarly high-risk infants in 2001 (Shinwell et al 2003). Still, the Vermont-Oxford 
Network data showed that 40% of ELBW infants in the participating institutions received 
postnatal DEX by the age of 28 days in 1999 (Barrington 2001), and 48% of European units 
also used DEX for non-intubated infants (Truffert et al 2003). The possible indications, 
quality, dosage, duration and time of administration of corticosteroid for the prevention or 
treatment of BPD remain one of the most controversial issues in neonatal medicine (Halliday 
2003). 
 
10.2.  Antenatal glucocorticoid treatment 
 
Prevention of neonatal diseases 
After their introduction for fetal maturation 30 years ago, antenatal glucocorticoids were 
slowly incorporated into clinical practice, due to the variable interpretations of the evidence 
leading to conflicting advise, fear of long-term adverse effects and advances in the care of 
VLBW infants. A meta-analysis of 15 randomized controlled trials showed them to reduce 
mortality, RDS, IVH and NEC (overall reduction in the odds about 40%, 50%, 60% and 70%, 
respectively) in infants born before 34 gestational weeks: Liggins & Howie 1972, Block et al 
1977, Morrison et al 1978, Papageorgiou et al 1979, Schutte et al 1979, Taeusch et al 1979, 
Doran et al 1980, Teramo et al 1980, Collaborative Group on Antenatal Steroid Therapy 
(CGAST) 1981, Schmidt et al 1984, Morales et al 1986, Carlan et al 1991, Garite et al 1992, 
Kari et al 1994 (Crowley 1995). The benefits were greater when the glucocorticoids were 
administered 24 hours - 7 days before birth or even earlier, additively to those derived from 
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surfactant, and in case of premature rupture of membranes. Even treatment <24 hours before 
birth decreased IVH (Kari et al 1994). Their effect on infection was equivocal, and no effect 
was found on PDA (Eronen et al 1993, Kari et al 1994) or BPD. The few available follow-up 
studies did not reveal adverse neurological outcomes (MacArthur et al 1982, CGAST 1984, 
Smolders-de Haas et al 1990); on the contrary, protective effects were suggested (Crowley 
1995). A study of an observational database of 35 000 VLBW infants supported the reduction 
in IVH but not in NEC and reported a decrease in PDA and an increase in infection (Wright et 
al 1995). In 1994, based on the meta-analysis, the NIH Consensus Development Conference 
recommended antenatal glucocorticoids for women at risk of premature delivery (24-34 
gestational weeks), as cost-saving therapies to reduce mortality and morbidity: either two 12-
mg doses of betamethasone given intramuscularly 24 hours apart or four 6-mg doses of DEX 
12 hours apart, preferably 24 hours - 7 days before birth, but even later. The role in high-risk 
conditions, such as hypertension and diabetes, was not established. Treatment was 
recommended even with the available surfactant, as the latter alone had little or no impact on 
the incidence of IVH or PDA. (NIH 1995) 
Thereafter, maternal administration increased, even as repeated courses after seven days 
for those who remained undelivered. Multiple courses were not recommended, as no 
additional short-term benefits were seen in non-randomized studies, but instead, there was 
increased mortality with lower gestational age (Banks et al 1999) and a trend towards more 
BPD (French et al 1999).  Randomized or quasi-randomized trials of 3700 infants showed a 
consistently significant reduction in mortality, RDS and IVH with no adverse consequences 
of a single course of betamethasone, DEX or hydrocortisone, but treatment >7 days before 
delivery was not proved effective (Crowley 2000), as initially suggested by Liggins & Howie 
(1972). In a further analysis of three randomized controlled trials of 551 infants (Guinn et al 
2001, Aghajafari et al 2002b, McEvoy et al 2002), repeated doses decreased the risk of any 
severe lung disease (Guinn et al 2001) and the need for surfactant (Guinn et al 2001, McEvoy 
et al 2002). No difference was found in perinatal death, IVH or PVL. (Crowther & Harding 
2003)   
 
Neurodevelopmental outcome after antenatal glucocorticoids 
Antenatal glucocorticoids prevent IVH (Crowley 1995, Wright et al 1995, Crowley 2000), 
and the first follow-up studies also suggested protection against adverse neurological outcome 
(MacArthur et al 1982, CGAST 1984, Smolders-de Haas et al 1990, Crowley 1995, Salokorpi 
et al 1997). Data on animal studies (Jobe et al 1998, Huang et al 1999, Whitelaw & Thoresen 
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2000, Aghajafari et al 2002a) and postnatal glucocorticoids (Yeh et al 1998, Shinwell et al 
2000) aroused concern about possible long-term effects on neurodevelopmental outcome. In a 
prospective cohort study, repeated courses were associated with a 4% reduction in head 
circumference at birth, representing a nearly 11% reduction in cranial volume (French et al 
1999) and presenting an increased risk for abnormal neurodevelopment (Hack et al 1991). In 
a retrospective study of 883 infants, DEX (11%) but not betamethasone (4.4%) was 
associated with an increased risk of cystic PVL, a major cause of CP, compared with no 
glucocorticoid treatment (8.4%) (Baud et al 1999). In the original trial of our study, abnormal 
brain ultrasound findings, including PVL, were decreased (Kari et al 1994), and in a 
prospective study of ELBW infants, they were not increased after antenatal DEX on hospital 
discharge (LeFlore et al 2002). No association was found between brain weight and antenatal 
glucocorticoids in preterm infants who died (Murphy 2001).  
 
Few long-term follow-up results of randomized antenatal glucocorticoid trials continued until 
school age or adulthood are available. In a Dutch follow-up trial of 81 adults born at 27-40 
gestational weeks in the 1970´s, those treated with a single course of betamethasone did not 
differ from placebo-treated controls in CP or cognitive function at the age of 20 years 
(Schutte et al 1980, Dessens et al 2000). Previous follow-up studies of 250 out of 304 
survivors after antenatal betamethasone (Liggins & Howie 1972, MacArthur et al 1982) and 
406 out of 739 infants after DEX trial (CGAST 1981, 1984), revealed no negative 
neurological outcome at six years or three years of age, respectively. In the previous 
Auckland trial, betamethasone-treated girls scored better than control girls in school 
behaviour. In the Collaborative study, mental and psychomotor development was assessed at 
nine and 18 months and cognitive abilities at 36 months of age.   
In an Australian cohort study, teenagers who had been exposed to antenatal betamethasone 
in the early 1980´s showed better cognitive functioning at 14 years of age compared to 
VLBW controls and tended to have less CP (Doyle et al 2000b). The cohort study of French et 
al (1999) assessed 327 infants at three years of age: CP was found in 7.8% of the non-
corticosteroid group, 5.1% of the single-course group, and none in the group given repeated 
courses. The disability rate did not differ, despite initial differences in head growth, but was 
small in all groups. 
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Growth after antenatal glucocorticoids 
Decreased birth weight has been associated with antenatal DEX (Bloom et al 2001) and with 
multiple courses of glucocorticoids (Banks et al 1999). In the study of French et al (1999), 
repetitive courses impaired fetal growth, but no difference persisted at the age of three years.   
In the follow-up studies of randomized trials, no harmful effects on growth, i.e. height, 
weight or head circumference, were reported at 3-20 years of age (MacArthur et al 1982, 
CGAST 1984, Smolders-de Haas et al 1990, Dessens et al 2000). After antenatal DEX, body 
weight and height were slightly greater at three years of age (CGAST 1984), and girls given 
betamethasone were taller and heavier at six years (MacArthur et al 1982) than the controls in 
the placebo group. The Dutch study reported a delay in puberty in boys (Smolders-de Haas et 
al 1990). 
In a non-random cohort study, the children exposed to antenatal betamethasone were 
significantly taller than those not exposed, with no difference in sexual development (Doyle et 
al 2000b).   
 
Respiratory morbidity and lung function after antenatal glucocorticoids 
Antenatal glucocorticoids halved the risk of RDS, but had no consistent effect on BPD at 28 
days (Crowley 1995, Wright et al 1995, Crowley 2000). Nor did a case-referent study of 1454 
VLBW infants born in the surfactant era show any change in BPD at 36 gestational weeks 
(Van Marter et al 2001). Repeated doses have been shown to decrease the risk of severe lung 
disease and the need for surfactant, but there are no data on long-term safety (Crowther & 
Harding 2003). 
In studies of lung function, infants treated with a single course of betamethasone were 
shown to have higher FRC and better respiratory system compliance than matched untreated 
infants within 36 hours, prior to surfactant treatment. No significant difference was found in 
specific compliance or Raw, suggesting that there was recruitment of alveoli without 
significant overdistension (McEvoy et al 2001). Compliance was higher after multiple courses 
(McEvoy et al 2000). 
Respiratory morbidity is infrequently assessed in follow-up studies of randomized trials. 
More hospital admissions because of infections or respiratory diseases during the first year 
were reported after betamethasone (Smolders-de Haas et al 1990) and more respiratory 
complications at 18 months of age after DEX (CGAST 1984).   
Data on the long-term effects of DEX treatment on lung function are sparse. Follow-up 
studies of 75 children 10-12 years after a betamethasone trial (Smolders-de Haas et al 1990) 
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and of 20 children six years after a DEX trial (Wiebicke et al 1988) revealed no negative 
effects of glucocorticoid on lung function. In a cohort study of betamethasone, no significant 
differences were seen in lung function, assessed by spirometry and body plethysmography, at 
the age of 14 years between those with and without exposure to glucocorticoids (Doyle et al 
2000b).  
 
Cardiovascular findings after antenatal glucocorticoids 
In randomized trials comparing the fetal effects of antenatal glucocorticoids, betamethasone 
reduced and DEX increased fetal heart rate variation (Mulder et al 1997), both induced 
profound suppression of heart rate acceleration and variability at 48 hours, with a more 
marked decrease after betamethasone (Rotmensch et al 1999), and the reversible fall in 
variability was preceded by an initial increase with no differences between the groups (Subtil 
et al 2003). All changes were reversible. In the meta-analyses of randomized studies, no effect 
was found on PDA (Crowley 1995), but the observational database showed a decrease in 
incidence (Wright et al 1995). No overall effect, but a beneficial effect on ductal closure in 
infants born at <30 gestational weeks was reported (Eronen et al 1993). 
Antenatal DEX did not appear to affect cardiac dimensions and blood flow velocity in 
preterm infants during the first month of age (Skelton et al 1998). No studies exist on the 
long-term effects of antenatal glucocorticoid on heart function or growth. 
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AIMS OF THE STUDY 
 
In this follow-up study of two randomized trials, we investigated the effects of antenatal or 
neonatal dexamethasone treatment on cardiopulmonary function, somatic growth and 
neurosensory development at school age in children born very prematurely, by using different 
lung function methods, cardiac evaluation, hospital data and questionnaires. Furthermore, we 
wanted to assess the possible role of inflammation in bronchopulmonary dysplasia. 
 
The specific aims of the present study: 
 
I  To assess the oscillometric method in detecting abnormalities of lung function 
in children with or without bronchopulmonary dysplasia, compared with 
conventional lung function tests. 
 
II  To study the possible inflammatory basis of abnormal lung function in 
bronchopulmonary dysplasia by measuring exhaled nitric oxide concentrations. 
 
III  To evaluate cardiopulmonary function, growth and neurosensory development 
after neonatal dexamethasone treatment for persistent respiratory failure. 
 
IV  To investigate cardiopulmonary function, growth and neurosensory 
development after antenatal dexamethasone treatment for imminent preterm birth. 
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PATIENTS AND METHODS 
 
1.  Patients 
 
The 49 children in the present study were born very prematurely in 1989-1991, at gestational 
ages of <31 weeks or birth weights of <1500 g, and they were treated in the Neonatal 
Intensive Care Unit of the Hospital for Children and Adolescents, Helsinki University Central 
Hospital. They were included in one of two randomized double-blind placebo-controlled 
trials: postnatal DEX therapy in VLBW infants at risk for BPD (Trial 1) (Kari et al 1993) or 
prenatal DEX therapy in conjunction with exogenous surfactant therapy (Trial 2) (Kari et al 
1994). They represent the major arms of multicentre trials, where the patients in Helsinki 
were randomized as separate groups. Three children participated in both trials. Additionally, 
one twin sister of a Trial 1 participant was included in the present study (I and II).  
 
The entry criteria for Trial 1 were: 1) birth weight <1500 g; 2) gestational age >24 weeks; 3) 
dependence on mechanical ventilation at ten days of age; and 4) no signs of ductus arteriosus, 
sepsis, gastrointestinal bleeding or major malformation. A total of 23 infants received either 
DEX (Oradexon®, Organon, Oss., The Netherlands) 0.5 mg/kg per day, divided into two 
doses, for one week (DEX group) or an equivalent volume of saline (placebo group). Open-
label DEX therapy was allowed after 28 days of age at the discretion of the attending 
neonatologist. During the initial hospitalization, three infants died: one boy in the DEX group 
and one boy and one girl in the placebo group. The 20 surviving children (DEX 10, placebo 
10) were invited to participate in this follow-up study: one child was excluded because of 
neurological handicap, one family refused to participate and two could not be traced. Thus, 16 
(80%) children participated in the present study (I, II and III). In addition, data on the 
neurological outcome of all non-participants were collected from hospital records up to the 
age of 5-7 years (III).    
 
In Trial 2, 112 pregnant women with imminent preterm delivery before 32 weeks of gestation 
were recruited and received either four doses of DEX (Oradexon®, Organon, Oss., The 
Netherlands), 6 mg at 12-hour intervals intramuscularly (DEX group) or an equivalent volume 
of saline (placebo group). 138 live-born babies were delivered (DEX 74, placebo 64). 
Fiftynine infants were born at <31 weeks of gestation (DEX 37, placebo 22), of whom 14 died 
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during the initial hospitalization and one at five months of age (DEX 6, placebo 9). The 44 
surviving children (DEX 31, placebo 13) were invited to participate in this follow-up study: 
nine of them could not be evaluated, but data on their outcome were collected from hospital 
records. A total of 35 (80%) children participated in the present study (DEX 87%, placebo 
62%) (I, II and IV). Besides, the limited data available on the neurological outcome of 43 
children at school age were analyzed (DEX 100%, placebo 92%) (IV). 
 
Eighteen healthy non-atopic children born at term were recruited as controls for the lung 
function tests. The study was approved by the institutional ethics committees. Written 
informed consent was obtained from the parents. 
 
2.  Neonatal and follow-up data collection 
 
Data on the initial hospitalization and supplemental oxygen requirements were collected in 
order to characterize the severity of the infants´ primary respiratory and neurosensory disease. 
The fraction of inspiratory oxygen (FiO2) was recorded at the postnatal ages of 2, 6, 12, 18, 
24, 48, 72, 96 and 120 hours. The mean FiO2 requirements during 120 hours were calculated 
on the basis of the areas under the curve. The duration of supplemental oxygen, FiO2 >0.4 
requirements and dependence on supplemental oxygen at the ages of 28 days and 36 and 40 
gestational weeks were recorded, as were the duration of ventilator treatment and initial 
hospitalization. BPD was defined as a requirement for supplemental oxygen at a postnatal 
gestational age of 36 weeks (Shennan et al 1988). The length of open-label DEX therapy after 
28 days was recorded. The diagnoses of IVH (Papile et al 1978), PVL (Bejar et al 1986) and 
ROP (International classification 1984) were established using standard methods. Abnormal 
brain ultrasound findings were defined as IVH or PVL. PDA was regarded as significant if it 
required indomethacin treatment or surgical closure. Small-for-gestational-age (SGA) infants 
weighed <-2 SD from the mean birth weight for each gestational week (Pihkala et al 1989). 
All hospital records were reviewed. Secondary hospitalization during infections, history of 
wheezing and use of glucocorticoids or bronchodilators were regarded as signs of respiratory 
morbidity. Major neurological problems and neuropsychological status at the age of five 
years, major visual and hearing deficits and the conclusions drawn from school maturity 
assessments were recorded. The diagnosis of CP was based on findings of abnormal muscle 
tone, exaggerated tendon reflexes and a positive Babinsky sign and on persistent or 
exaggerated primitive reflexes, dyskinesia or ataxia. The degree of disability was classified 
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according to Jones et al (1995): severe disability was defined as CP, severe global delay or 
sensory or other impairment necessitating special school attendance. Moderate disability was 
defined as mild CP, severe deafness, moderate global delay (extra help needed at school, 
assessment of global retardation or language problems) or home oxygen use beyond three 
years of age, but not severe enough to require education at a special school. Possible 
cardiovascular medication or intervention was recorded. 
 
3.  Study protocol 
 
All of the 49 children enrolled in the study were serially evaluated during 1998-1999 in the 
Outpatient Department of Allergic Diseases, Helsinki University Central Hospital. At the first 
visit, the principal investigator carried out the physical examination. The transformation of 
body height into standard deviations (SDs) was based on the Finnish growth standards, with 
standard curves constructed using group mean values and SDs for height at certain ages and 
according to gender (Sorva et al 1990). Relative weight was calculated as the percentage 
deviation from the median weight of Finnish children of the same height and gender. 
Moderate or severe neurological impairment was recorded. The questionnaires focused on 
respiratory symptoms and medication used during the preceding year and the history of 
smoking or atopy in the family. Frequent respiratory symptoms were defined as dyspnea, 
prolonged coughing for >2 months or recurrent coughing during exercise or at night. Impulse 
oscillometry, flow-volume spirometry and pulmonary diffusing capacity test were done in the 
Lung Function Laboratory of the Division of Allergy, Helsinki University Central Hospital. 
The principal investigator, unaware of the neonatal history of each child at the time of testing, 
supervised the lung function tests, supported the children to succeed in the test performance 
and evaluated their co-operation for further lung tests. The children were examined clinically 
when free of respiratory infections or allergic symptoms. Skin tests were performed by skin 
prick with ten common environmental allergen extracts (birch, timothy grass, meadow fescue 
and mugwort pollens, cat, dog, horse and cow epithelial danders,  house dust mite Dermato-
phagoides pteronyssimus and spores of Cladosporium herbarum), negative vehicle and 
positive histamine hydrochloride (10 mg/ml). Atopy was defined as at least one wheal 
reaction >3 mm in diameter in the absence of a response to the negative control solution. 
 
During the second visit, exhaled nitric oxide measurement and whole-body plethysmography 
were performed in the Division of Clinical Physiology, Helsinki University Central Hospital. 
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The children were to have been clinically free of respiratory infections or allergic symptoms 
for at least three weeks. Children on glucocorticoid inhalation therapy during infections were 
examined more than three weeks after the discontinuation of their glucocorticoid, and those 
on regular glucocorticoid inhalation therapy had a 24-hour glucocorticoid-free interval before 
the measurement. β2-sympathomimetic agents were not allowed for 12 hours before the 
measurement. Exposure to tobacco smoke and physical exercise were avoided on the same 
morning.   
 
During the third visit, a chest X-ray was taken, echocardiography was performed, and 
electrocardiogram (ECG) readings were analysed by a pediatric cardiologist at the Division of 
Pediatric Cardiology, Helsinki University Central Hospital. 
. 
4.  Lung function methods 
 
Flow-volume spirometry (I to IV) 
Flow-volume spirometry was performed with a pneumotachometer-based spirometer 
(Spirotrac III, Vitalograph Ltd, Buckingham, UK). A nose clip was used, and a visual 
computer program helped to optimize the forced exhalations. At least three acceptable forced 
expiratory curves were recorded according to the reproducibility criteria of the American 
Thoracic Society (ATS) (1995). The curve with the highest sum of forced expiratory volume 
in one second (FEV1) and forced vital capacity (FVC) was selected for the analysis. FVC, 
FEV1 and forced expiratory flow at 50% of FVC (FEF50) were recorded, and the results were 
expressed as percentages of predicted value (Polgar & Promadhat 1971). Spirometric 
parameters were measured before and 15 min after the inhalation of 0.3 mg of salbutamol 
(Ventoline®, Glaxo, Greenford, UK) via a large-volume plastic spacer (Volumatic®). The 
bronchodilator response was expressed as the percentage change in FEV1 from baseline 
(∆FEV1). Abnormal basic spirometric finding was defined as FVC<80%, FEV1<80% or 
FEF50<62% of predicted values, and ∆FEV1>15% was considered as an increased 
bronchodilator response. 
 
Impulse oscillometry (I, III and IV) 
Impulse oscillometry (Jaeger GmbH, Würzburg, Germany) (Vogel & Smidt 1994) was 
performed, when the child was sitting and breathing quietly through a mouthpiece. A nose 
clip was used, and the cheeks were supported by the investigator, to minimize pressure loss 
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through the upper airway shunt. The impulse interval was set to 0.3 seconds, and by using 
Fast Fourier transformation, the resistance (Rrs) and reactance (Xrs) of the total respiratory 
system were calculated as functions of an oscillation frequency of 535 Hz. The 
measurements were repeated at least three times, and three acceptable, visually uniform 
recordings were used to calculate a mean value for Rrs at 5, 10 and 20 Hz (Rrs5, Rrs10, 
Rrs20) and for Xrs at 5 and 10 Hz (Xrs5, Xrs10) and the resonance frequency (fres; the 
frequency where reactance has the value of zero). The results were expressed as SDs of 
reference values (Duiverman et al 1985). IOS measurements were repeated 15 min after the 
inhalation of 0.3 mg of salbutamol. The bronchodilator response was expressed as the 
percentage change in Rrs5 from baseline (∆Rrs5). Abnormal IOS findings were defined as 
Rrs5>1.65 SD or Xrs5<-1.65 SD, and ∆Rrs5>30% was considered as an increased 
bronchodilator response. 
 
Pulmonary diffusing capacity test (I to IV)   
Pulmonary diffusing capacity and static lung volumes were measured using the single-breath 
method (Cotes et al 1993) (PFT, Jaeger GmbH, Würzburg, Germany). A volume of 90% of 
inspired vital capacity was used for breath holding; the washout volume was preset at 500 ml 
and the sample for expiratory gas fraction was 750 ml. Mean values of three acceptable 
measurements were used for the analysis of pulmonary diffusing capacity (DLCO) and the 
diffusing coefficient (KCO) for carbon monoxide. The results were expressed as percentages of 
the predicted values of Polgar & Promadhat (1971) for static lung volumes (I) and for 
diffusing capacity (II), and as percentages of the predicted values of Cotes et al (1979) for 
diffusing capacity (I, III and IV). 
 
Whole-body plethysmography (I) 
Whole-body plethysmography (Body-Screen II, Jaeger) was performed for those who showed 
sufficient cooperation in previous lung function studies. The mean values of three acceptable 
measurements of total lung capacity (TLC), residual volume (RV), airway resistance (Raw) 
and specific conductance (SGaw) were recorded, and the RV/TLC ratio was recorded to assess 
hyperinflation. The reference values of Polgar & Promadhat (1971) were used for the 
analysis. 
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5.  Exhaled nitric oxide (II) 
 
Exhaled nitric oxide was measured using a chemiluminescence analyzer (Sievers 270B, 
Boulder, CO) (Kharitonov et al 1997) with a rapid-response time (<200 ms) and an accuracy 
of +1 ppb (parts per billion). In addition, the analyzer also measured expiratory flow and 
exhaled volume in real time. The sampling rate through the reaction chamber of the analyzer 
was 250 mL/min for all measurements. The analyzer was calibrated daily, using NO-free 
oxygen to set the absolute zero and certified NO gas of 184 ppb NO in nitrogen (AGA 
Edelgas, Germany). 
For eNO measurements, after inhaling NO-free oxygen, the children exhaled slowly from 
TLC for 15 seconds through a flow resistor (Hans Rudolp, Model 7100R, 50cmH20/L/s, flow 
range 0-0.5 L/s), which created a positive pressure necessary to close the soft palate. Due to 
the small lung volumes of the children, the target flows recommended by the European 
Respiratory Society (ERS) (Kharitonov et al 1997) (0.16-0.25 L/s) appeared to be unsuitable, 
as they presumed a volume of at least 2.4-3.7 L for 15-second exhalation. Therefore, lower 
target flows were used in this study (0.10-0.20 L/s). A visual computer program was used to 
help to maintain the flow as fairly constant. A nose clip was used, and the cheeks and lips 
were supported to prevent any air leak. During a steady exhalation, eNO reaches a plateau 
after 5-10 seconds, while the exhaled volume continues to increase. The mean value of the 
last three seconds of the end-expiratory plateau of NO concentration was taken for analysis. 
The results of the analyses were computed and graphically displayed on a plot showing eNO 
levels, flow and volume against time and expressed as eNO concentration (ppb) and NO 
output (pmol/s). At least three successive recordings were made, with a coefficient of 
variation of <10%. The mean value of the measurements was recorded on the case record 
form. 
 
6.  Cardiological measurements (III and IV) 
 
ECG criteria for right ventricular hypertrophy were defined as R wave >20 mm or >S wave at 
lead V1. Incomplete right bundle branch block (RBBB) was registered. Cardiac volume was 
derived from the size of the heart on plain chest x-ray. The anatomy and function of the heart 
and the large vessels were studied using two-dimensionally guided, pulsed, continuous-wave 
and colour Doppler equipment (Acuson 128 XP machine, Mountain View, CA, USA) with 
2.5, 3.5 and 5.0 MHz probes and recorded on videotape. Pulmonary arterial pressure was non-
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invasively assessed by measuring tricuspid valve regurgitation flow (Farstad et al 1995, 
Subhedar et al 2000). In the main pulmonary artery, peak systolic velocities (cm/s) and 
acceleration time (ms) were registered.  
  
7.  Statistics 
 
The results of lung function tests were expressed as percentages or SDs of predicted values. In 
Study I, ANOVA with Bonferroni/Dunn´s application for multiple comparisons was used to 
compare the lung function test results of the thre groups. Pearson´s correlation coefficient was 
calculated for the relationship between the different lung function tests. Kappa (κ) statistics 
were used to describe the agreement between spirometry and the IOS method, and 
McNemar´s test to compare the agreement of oscillometric variables with spirometry. A p-
value <0.05/3=0.017 was considered significant in group comparisons, otherwise p<0.05. In 
the Studies II to IV and in supplemental analyses of the whole population, the Kruskall-Wallis 
non-parametric test was used to determine the significances of the differences between the 
three groups. The Mann-Whitney test and the χ2 test with continuity correction were used for 
the comparisons between two groups. P<0.05 was considered significant. Spearman´s rank 
correlation was used to evaluate the association between individual values of neonatal data, 
lung function and cardiological measurements. 
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RESULTS 
 
1.  Population characteristics 
 
Children born very prematurely (All, I to IV) 
The basic perinatal and neonatal data of the study children and the different subgroups are 
presented in Table 2. The children were born at 24.1 to 30.9 gestational weeks with birth 
weights of 600-1575 g (I to IV). 45% of them were male and 12% SGA. 55% had received 
antenatal DEX. All except one child required mechanical ventilation after birth, which was 
provided by a pressure-limited Baby Bird ventilator (Bird Corporation, Palm Springs, CA, 
USA). 84% had RDS, and 43% received surfactant for treatment. 6% had air leak syndrome. 
73% required indomethacin and 6% surgical ligation for PDA. At the age of 28 days, 29% 
were on ventilator support and 63% on supplemental oxygen. 33% were on supplemental 
oxygen at 36 gestational weeks and 22% at 40 gestational weeks. 33% received postnatal 
DEX before two months of age for weaning from the ventilator. 22% had IVH grade 1-4, 8% 
IVH grade 3-4 and 28% abnormal brain ultrasound findings. 6% had NEC, 12% had ROP, 
and 8% needed cryocoagulation (not shown in the original studies). 
 
Children with BPD (All, I and II)  
Apart from the more long-term need for supplemental oxygen, the BPD children had 
significantly lower gestational age (I) and birth weight and a longer need for ventilator 
treatment and initial hospital care than those with no BPD (I and II). Subsequent hospital data 
on oxygen need caused one child to be re-classified into the BPD group after the completion 
of Study I, and therefore, in the subsequent studies, 16 children had BPD and 33 did not. 
 
Atopic children (II) 
The difference in gestational age was not significant, but the atopic children had higher birth 
weight and a shorter need for initial respiratory support and hospital care (p<0.01) than the 
non-atopic children. 
 
Children in the postnatal dexamethasone study (III) 
The DEX and placebo groups did not differ in basic neonatal data. One child in each group 
had received antenatal DEX, and 3 out of 16 received surfactant therapy for RDS. Half of the  
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children in the placebo group and 25% in the DEX group received open-label DEX treatment 
after the trial. Half of the children in each group had BPD. 
 
Children in the antenatal dexamethasone study (IV) 
Abnormal brain ultrasound findings were more common in the placebo group than in the 
DEX group (p=0.02), which was the only significant difference in the neonatal data. 33% of 
the infants in the DEX group and all in the placebo group received indomethacin for PDA 
(p=0.06); nor was the difference in surfactant therapy (DEX 52%, placebo 88%) or ROP 
(DEX 7%, placebo 25%) significant. All of the 6 SGA infants were in the DEX group. 11% in 
the DEX group and 38% in the placebo group received postnatal DEX treatment. One fourth 
in each group had BPD. 
 
2.  Growth 
 
Children born very prematurely (All, I to IV)  
The demographic data of all study children and the non-atopic control children born at term 
are presented in Table 3. The study children did not differ significantly from the controls in 
age, height, weight (I and II) or relative weight. However, standardized height was lower in 
the prematurely born children than in the controls (p=0.03 in II; p=0.008 in All); this 
difference was significant in boys (p=0.007 in All, not shown in the studies), but not in girls. 
 
Children with BPD (All, I) 
Despite their lower gestational age and birth weight, the BPD children did not differ 
significantly at school age in height, weight (I) or standardized height, but they weighed less 
after adjustment for height and gender than the non-BPD children (p=0.03, not shown in the 
studies). 
 
Children after postnatal dexamethasone treatment (III) 
The children treated with DEX did not differ significantly from the placebo-treated children 
or the controls in height, standardized height, weight or relative weight. Standardized height 
was lower in the placebo group than in the controls (p=0.006). No significant correlation was 
found between the duration of DEX therapy before one year of age and the variables of 
growth (not in Tables). 
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Children after antenatal dexamethasone treatment (IV) 
Height, standardized height, weight and relative weight did not differ significantly between 
the children given antenatal DEX or placebo and the controls. Standardized height showed a 
tendency towards a difference (p=0.05) between the three groups; further comparisons proved 
it to be lower in the placebo group than in the control group (p=0.03). Adjusted for gender, 
this difference was significant in boys (p=0.01) (not shown in the studies). 
 
 3.  Respiratory symptoms and medication 
 
Children born very prematurely (All, I, III and IV) 
Table 4 shows the respiratory symptoms and medication of the study children in the different 
subgroups. 33% received glucocorticoid inhalations at 12 months and 37% at 24 months of 
age. One child was on oral systemic glucocorticoid until the age of 7.5 years. Adenoidectomy 
was performed on 57% of the children, and 39% needed tympanostomy tubes. Regarding the 
symptoms during the preceding year, 22% were reported to have asthma, 29% dyspnoea, 35% 
prolonged cough for >2 months, 12% cough during the pollen season, 14% on exercise and 
18% at night. A total of 49% reported either dyspnoea or prolonged cough. Glucocorticoid 
inhalations were used regularly by 5 (10%) and occasionally by 8 (16%) children. Combined 
with glucocorticoids, 4% used bronchodilators and 4% chromone inhalations regularly. 41% 
used β2-sympathomimetic agents. None had required hospitalization because of respiratory 
symptoms during the preceding year. Previous diagnosis of asthma, i.e. a history of asthma 
symptoms and regular therapy, correlated significantly with the use of glucocorticoids and 
bronchodilators and cough during the pollen season, but not with cough on exercise or at 
night, nor was the correlation with frequent symptoms during the preceding year significant. 
Dyspnoea or prolonged cough associated with lower age (p=0.02) and shortness for age 
(p=0.02) at the time of the study, but not with gestational age or birth weight. The use of 
glucocorticoid inhalations associated with lower age (p=0.007), low birth weight (p=0.02) and 
need for ventilator treatment (p=0.007), oxygen supplementation (p=0.02) and initial hospital 
care (p=0.02) (not shown in the studies). Worse exercise tolerance compared to others and at 
school, subjectively assessed by parents, was reported for 14 children: a correlation was found 
with shortness for age (p=0.046), low birth weight (p=0.03), ventilator treatment (p=0.03), 
oxygen supplementation (p=0.009) and initial hospital care (p=0.01). Only 3 of these 14 
children were free from severe or moderate disability (p=0.001) (not shown in the studies). 
Two children received medication for epilepsy (I). 
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sympathomimetic agents tended to be (p=0.07) more common in the children with BPD 
during the preceding year. 38% of the BPD and 45% of the non-BPD children had had neither 
prolonged respiratory symptoms nor inhalation therapy during the preceding year (not shown 
in the studies). 
 
Children after postnatal dexamethasone treatment (III) 
In the DEX group, 50% received glucocorticoid inhalations at 12 months and 63% at 24 
months, and in the placebo group, 50% and 50% did so, respectively; in addition, one child in 
the latter group received oral systemic glucocorticoid by the age of 7.5 years. Frequent 
respiratory symptoms during the preceding year were reported by 38% in each group. In the 
DEX group, none received regular glucocorticoids, although occasional use of inhalations 
was common. In the placebo group, one child out of 8 was on regular glucocorticoid 
inhalation, and 2 used β2-sympathomimetic agents occasionally. One fourth in each group had 
had neither prolonged respiratory symptoms nor a need for inhalations during childhood. No 
significant differences were seen in respiratory symptoms or medication associated with 
postnatal DEX treatment. 
  
Children after antenatal dexamethasone treatment (IV) 
In the DEX group, 26% received glucocorticoid inhalations at 12 months and 26% at 24 
months, compared with 25% and 50% in the placebo group. Half of the children in each group 
reported frequent respiratory symptoms during the preceding year. In each group, 2 children 
were on regular glucocorticoid inhalation (DEX 7%, placebo 25%), and β2-sympathomimetic 
agents were used commonly (DEX 44%, placebo 38%). The 2 children on regular inhaled 
bronchodilators were in the placebo group (p=0.07). One fourth in each group were free from 
frequent respiratory symptoms and inhalations until school age. Antenatal DEX treatment did 
not associate with respiratory symptoms or medication. 
 
4.  Smoking in the family (I to IV) 
 
Exposure to tobacco smoke was common in this series of children born very prematurely, 
defined as smoking during pregnancy (33% from hospital records, 25% reported), maternal 
smoking (39%), smoking within the family (45%) or smoking at home (6%) (not shown in the 
studies), with no difference between the subgroups in individual studies (III and IV) (I and II, 
not shown in the studies). 
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Influence on growth 
No significant correlation emerged between maternal smoking or smoking during pregnancy 
and growth (III) (in All, not shown in the studies). 
  
Influence on respiratory symptoms 
No associations were found between maternal smoking or smoking during pregnancy and 
dyspnea or prolonged cough (III and IV). Of the 15 study children with no prolonged 
respiratory morbidity and no need for inhalation during childhood, 60% had smoking 
mothers, and 47% had mothers who had smoked during pregnancy (not shown in the studies). 
  
Influence on lung function  
Maternal smoking or smoking during pregnancy was not associated with basic lung function 
as assessed by spirometry or oscillometry. However, maternal smoking or smoking in the 
family associated with poorer diffusion capacity at school age  (see results in page 73). 
 
5.  Atopy 
 
Children born very prematurely (All, II) 
30% of the families reported having medically diagnosed atopy and 32% probably atopic 
symptoms; 39% had animals. 12 out of 48 (25%) study children were skin prick-positive (not 
shown in the studies); one child refused to be tested. The atopic children did not differ 
significantly from the non-atopic children in gestational age (p=0.06), but they had higher 
birth weight (p=0.001) and a shorter duration of ventilator treatment (p=0.001), oxygen 
therapy (p=0.007) and initial hospital care (p=0.001) (II; p<0.01 in All, not shown in the 
studies). None of the skin prick-positive children had received postnatal DEX, differing 
significantly from the skin prick-negative ones (p=0.01). Prick positivity correlated neither 
with respiratory symptoms nor with medication (not shown in the studies). 
 
Children with BPD (All, II)  
In Study II, only one out of 12 (8%) BPD children had positive skin prick tests compared with 
9 out of 27 (33%) non-BPD children. In the whole group of study children, this finding of less 
atopy in the BPD group (1 out of 16) compared with the non-BPD group (11 out of 32) was 
statistically significant (p=0.04) (not shown in the studies). 
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Xrs5 were significantly associated with FVC and FEF50 as well. Rrs5 was significantly 
associated with Raw (r=0.63, p<0.0001), but showed higher values than Raw at low values of 
resistance and lower values at resistance values >1 kPa/L/s. Xrs5 was significantly related to 
RV (r=0.43, p<0.01) and RV/TLC (r=0.57, p=0.0004), but not to either DLCO or KCO.   
Low FEV1 was associated with increased Rrs5 in 10 and with decreased Xrs5 in 13 out of 
18 children; correspondingly, normal FEV1 was associated with normal Rrs5 in 22 and with 
normal Xrs5 in 27 out of 30 children. Rrs5 agreed with FEV1 at a low level (κ=0.29, 95% 
confidence interval (CI): 0.00-0.57) and Xrs5 at a moderate level (κ=0.64, 95% CI: 0.41-
0.87). Xrs5 yielded significantly more concordant information with spirometry than Rrs5 
(p=0.02). ∆FEV1 correlated significantly with the bronchodilator response in Xrs5 (p=0.02) 
and inversely with the initial FEV1 (p=0.0002) (not shown in the studies). 
 
Children born very prematurely (I and II) 
The children born very prematurely showed significant differences in basic lung function 
adjusted for height-dependent predicted values compared with the full-term controls: in 
spirometry, the FVC, FEV1 and FEF50 values were lower (I and II) and the bronchodilator 
response higher (II); in IOS, Rrs5, Rrs10 and fres were higher and Xrs5 and Xrs10 lower than 
in the controls (I); in the diffusing capacity test, DLCO (II), KCO and VC were lower and RV 
higher than in the controls (I). Thus, pulmonary function studies showed obstructive 
ventilatory defects, increased airway resistance, decreased airway reactance, pulmonary 
hyperinflation and decreased diffusing capacity among preterm children compared with full-
term controls. The use of inhaled medication during the preceding year associated with 
impaired lung function: both glucocorticoids and β2-sympathomimetics with FEV1 (p=0.0003 
for glucocorticoids, p=0.0008 for β2-sympathomimetics), FEF50 (p=0.0001 and p=0.005, 
respectively), Rrs5 (p=0.01 and p=0.002), Xrs5 (p=0.003 for both), Raw (p=0.02 for both) and 
SGaw (p=0.002 for glucocorticoids, p=0.01 for β2-sympathomimetics), but not with the gas 
exchange variables. Frequent respiratory symptoms did not correlate with the values of lung 
function tests. Worse exercise tolerance compared to others and at school, assessed by 
parents, associated with lower FEV1 (p=0.02) and SGaw (p=0.04) and tended to correlate with 
lower FVC (p=0.057) and FEF50 (p=0.055); no correlations were found with the variables of 
IOS or diffusing capacity. 
Twentythree out of 48 (48%) children had abnormal findings in basic spirometry and 21 
out of 48 (44%) in IOS (Figure 2); the bronchodilator response was significant in 8 out of 45 
(18%) in FEV1 and in 17 out of 47 (36%) in Rrs5. 
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Children after postnatal dexamethasone treatment (III) 
Spirometry and IOS showed significant impairment in pulmonary function in both study 
groups compared with the controls´ values (Table 6). FVC was higher in the DEX group 
(p=0.04), this being the only significant difference between the DEX and placebo groups. In 
IOS, Rrs5 was higher in the placebo group and Xrs5 was lower in the DEX group as signs of 
airway obstruction, and the bronchodilator response was increased in both groups compared 
with the full-term controls. DEX treatment was not shown to have any negative effect on 
pulmonary outcome. 
 
Children after antenatal dexamethasone treatment (IV) 
The study children had significantly impaired basic spirometric values and increased ∆FEV1, 
suggesting bronchial lability (Table 6). The more pronounced bronchodilator response in the 
placebo group was the only significant difference between the study groups in height-adjusted 
spirometric values (p=0.01). IOS revealed no significant differences between the DEX and 
placebo groups. Compared with the control group, Rrs5 was significantly higher and Xrs5 
lower in both study groups. Diffusing capacity test failed in 7 DEX and 3 placebo children 
and in 5 controls, thus rendering the comparisons between the preterm groups invalid. 
However, the mean DLCO and KCO values were significantly lower in all study children than 
in the controls. Antenatal DEX treatment was not shown to have any negative effect on 
pulmonary outcome. 
 
Effect of smoking 
Basic spirometric, oscillometric and body-plethysmographic values did not correlate with 
maternal smoking or smoking during pregnancy (III and IV). Nor did the values of the 
diffusing capacity test correlate with smoking during pregnancy. However, in Study IV, the 
prematurely born children with smoking mothers had significantly lower DLCO values 
(p=0.009) and a slight tendency towards lower KCO values (p=0.08) compared with the 
children of non-smoking mothers. Smoking in the family also tended to correlate with lower 
DLCO (p=0.08) and KCO (p=0.08) (IV); the difference in KCO was significant in all study 
children (p=0.02, not shown in the studies). 
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Influence of atopy, familial smoking or glucocorticoid inhalation 
In the prematurely born group, the atopic children had higher mean (SD) eNO values than the 
non-atopic ones [14.8 (14.2) vs 6.3 (4.5) ppb, p=0.02] and higher mean (SD) NO outputs of 
68.7 (54.6) and 36.8 (33.8) pmol/s, respectively (p=0.04) (Figure 3). The eNO concentrations 
and NO output values of the non-atopic study children did not differ significantly from those 
of the controls. Gender and exposure to smoking in the family were not significant predictors 
of eNO concentrations or output in the study children, nor was the use of inhaled 
glucocorticoids during the first two years of life or during the preceding year. 
  
Non-atopic children with BPD  
Due to the significant association of atopy with increased eNO in our study and of 
glucocorticoids with decreased eNO in previous studies, we excluded the 10 atopic children 
and the 3 children on regular glucocorticoid inhalation therapy from the further analyses. Of 
the remaining 27 non-atopic study children,  9 had a history of BPD and 18 had no BPD. 
These two groups did not differ in gestational age or demographic data at the time of the 
study, but the BPD children had lower birth weights and needed more oxygen 
supplementation, as by definition, and ventilator treatment (Tables 2 and 3). Despite 
significant differences in spirometry, the eNO concentrations did not differ between the BPD, 
non-BPD and control children [6.8 (4.6), 5.9 (4.8) and 6.4 (4.3) ppb, respectively], nor did the 
eNO output values [48.7 (47.9), 29.5 (23.6) and 30.8 (24.8) pmol/s] (Figure 3). In the non-
atopic children born very prematurely with a history of BPD, we found no evidence of airway 
inflammation associated with increased eNO concentration. No association was found 
between eNO levels and the severity of chronic lung disease, determined by conventional 
lung function tests, either.  
 
8.  Cardiac function 
 
Children after postnatal dexamethasone treatment (III) 
No significant difference between the study groups was seen in cardiac volumes, Doppler-
mode-derived variables of pulmonary flow (peak velocity or acceleration time) or left 
ventricular function (Table 8). Tricuspid valve regurgitation of >30 mmHg was detected in 3 
children in the DEX group and one child in the placebo group. The placebo group child had 
elevated pulmonary arterial pressure of 42 mmHg in cardiac catheterization at three years of 
age and was treated with digoxin and nifedipine. In the follow-up at eight years of age,  
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cardiomyopathy was seen. One girl in the DEX group had a tiny PDA 1.5 mm in diameter. No 
murmur was heard, and no closure was needed. None required cardiovascular medication. 
51% of the children born prematurely presented with RBBB in ECG. These children had 
more severely impaired values of FEV1 (p=0.03), Rrs5 (p=0.02) and Xrs5 (p=0.02) than those 
without RBBB. However, RBBB did not associate with BPD or PDA. 
 
9.  Neurological follow-up 
 
Children after postnatal dexamethasone treatment (III) 
At the age of five years, 50% of the children in each study group needed physiotherapy, 
occupational therapy or evaluation for the most appropriate type of school because of 
neurological impairment or difficulties in speech, learning or comprehension. All were able to 
walk without aid or support. All of the children in the DEX group attended normal school, 
and 3 of them had CP: one girl with mild, spastic diplegia and mild cognitive difficulties 
needed a personally adjusted course in mathematics as well as physiotherapy; one girl with a 
shunted hydrocephalus, epilepsy, mild, spastic diplegia and strabismus needed a personal 
assistant at school (IVH grade 3-4); one boy with mild, spastic hemiplegia needed 
physiotherapy, and one boy with no previous problems needed speech therapy because of 
reading difficulties (Table 9). In the placebo group, 7 (88%) children attended normal school, 
and 2 of them had CP: one girl who had received oxygen therapy for 4.5 years had a personal 
assistant because of moderate spastic diplegia, and she also needed physiotherapy, and one 
boy with mild, hypotonic diplegia had a personal assistant and had problems in mathematics 
(IVH grade 2-3), but spoke three languages. One girl attended a preparatory class before 
entering normal school. Another mentally retarded girl attended a special school for blind 
children because of a severe bilateral visual deficit caused by ROP. 
Thus, 38% of the children in the DEX group and 25% in the placebo group had CP. In the 
DEX group, 38% were moderately disabled, while in the placebo group, 25% were severely  
and 25% moderately disabled. The neurodevelopmental outcome at school age did not differ 
significantly between the DEX and placebo groups. 
The data from the hospital records of the 4 children lost to this follow-up did not add to 
any differences between the groups, as no CP was found, all could walk without support and  
attended or planned to attend normal school, and one child in each group was moderately 
disabled. 
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Thus, 11% of the children in the DEX group and 50% in the placebo group had CP. 22% 
of the children in the DEX group and 75% in the placebo group were either severely or 
moderately disabled.  In the DEX group, the rate of normal school attendance was higher 
(p=0.01), and there were fewer instances of severe to moderate disability (p=0.02) and a 
tendency towards a lower incidence of CP (p=0.06) than in the placebo group.  
The limited data on the neurological outcome of 8 out of the 9 children lost to this follow-
up study (Table 1 in IV) confirmed these results. Furthermore, out of the 59 infants in the 
original antenatal DEX study, 26 of the 37 (70%) children in the DEX group survived without 
CP compared with 6 of the 21 (29%) in the placebo group (p=0.003).
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DISCUSSION 
 
1.  Methodological aspects 
 
Our study population consisted of VLBW children born very preterm, who participated in one 
of the following two randomized placebo-controlled perinatal trials: study of neonatal DEX 
given to severely ill ventilator-dependent infants at a high risk of BPD (Trial 1) (Kari et al 
1993) or very preterm infants born to mothers who participated in the study of antenatal DEX 
in imminent preterm birth (Trial 2) (Kari et al 1994). All infants were treated in the same 
hospital during a 3-year period, with no major changes in ventilator treatment. Thus, the 
infants in Trial 1 were a relatively homogenous group, with minimal variations in neonatal 
treatment. The infants in Trial 2 were born after the anticipation of preterm birth, with the best 
possible perinatal care available. The latter setting may underestimate the morbidities and the 
long-term sequelae of very preterm birth. 
Altogether 49 (79%) of the 62 recruited children participated in this follow-up. About one 
third of the non-participants refused, one third were excluded because of severe neurological 
problems, and the rest were not traced. The perinatal data of the non-participants did not differ 
significantly from those of the study children. The neurological outcome data were extracted 
from hospital records in the case of 61 (98%) children. Inclusion of the non-participants in the 
neurologic assessment did not change the results (III and IV). Therefore, our study children 
can be considered good representatives of the original trials. 
Despite occasional severe neurological impairments, all could perform the IOS procedure 
and all but one the spirometric measurements. The children with most severe lung disease or 
small lung volumes could not perform the diffusing capacity test or the body 
plethysmography. This may underestimate the impairment of lung function or conceal the 
differences between the subgroups. However, occasional children with severe neurological 
handicap, with or without lung disease, also either failed in performance or were 
prospectively excluded. Even though the study population was small, the lung function tests 
were carefully standardized with low variability (<5% in FVC and FEV1 and <10% in eNO). 
All cardiac measurements were performed by the same pediatric cardiologist.  
Only non-atopic full-term children were selected as a control group in the lung function 
studies. The larger age range in the control group compared to the study groups made the 
range of body heights, to which the lung function results were adjusted, very similar in all groups. 
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Compared to IOS, spirometry showed significant concordance, as did also body 
plethysmography. Still, the different methods could not be compared in the children with the 
most severe lung disease or the smallest lung volumes. One BPD child was misclassified into 
the non-BPD group in Study I, but this had no significant effect on the results. (I) 
The impairment of lung function was compared with one marker of inflammation, eNO. 
To avoid the bronchodilator effect, eNO measurements were performed at another visit than 
spirometry, which could influence the associations. (II) 
The sample size in Study III was too small to warrant definite conclusions. The power of 
this study alone is low, but it will be of value in future meta-analyses. The homogeneity of the 
group (Trial 1), the successful lung function tests and the abundant neurological data are a 
strength, but the frequent use of DEX after the study could be considered a weakness of the 
study. 
In Study IV, the size of the placebo group was small, due to the small number of infants 
born very preterm and the high mortality (Trial 2). This emphasizes the better outcome in the 
original DEX group, if perinatal death is included. This group was heterogenous in perinatal 
respiratory morbidity; differences in treatment may individually affect the long-term outcome, 
causing bias, or represent the effects of antenatal DEX. This follow-up is important in meta-
analyses of the long-term outcome, especially as new placebo-controlled randomized studies 
will hardly follow, because of the well-established short-term benefits of antenatal DEX. 
 
Definition of bronchopulmonary dysplasia 
We used a simple criterion for BPD, i.e. supplemental oxygen at 36 gestational weeks. 
Despite the variations in treatment strategies, discontinuation of oxygen is one clinical 
descriptor of infant stability. In our study, the diagnosis of BPD is used more as a tool to 
divide the preterm born children into those at a high risk and those at a risk of long-term 
sequelae of prematurity than as a strictly defined disease. The infants in Trial 1 were born 
before the introduction of antenatal glucocorticoid and surfactant therapy into common use, 
and due to the entry criteria, represent VLBW children with severe lung disease and hence 
with a high incidence of BPD (50%). The infants in Trial 2 were born at the beginning of the 
era of antenatal glucocorticoid and surfactant therapy, and the incidence of BPD was 23%. 
The differences in the definitions of BPD make comparisons of the incidences and long-term 
sequelae in studies between different centres and periods extremely rough. 
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2.  Oscillometric method  
 
In our study, IOS yielded lung function information concordant with conventional methods, 
such as spirometry and whole-body plethysmography, and served well in studying 
prematurely born children. The findings probably reflect the peripheral or more widespread 
airway obstruction and are most valuable in combination with other lung function tests.  
 
Using the oscillometric method, the mechanical properties of the lung have been described 
previously in children with asthma (Solymar et al 1984, König et al 1984, Lebecque et al 
1987, Bisgaard & Klug 1995, Klug & Bisgaard 1996), cystic fibrosis (Lebecque & Stănescu 
1997, Hellinckx et al 1998) and chronic respiratory symptoms (Timonen et al 1997). In 
asthma, airway obstruction is associated with increased Rrs, the values measured at the lowest 
oscillatory frequencies (2-5 Hz) showing the best sensitivity (Clément et al 1983, Solymar et 
al 1984, Bisgaard & Klug 1995). This pattern of abnormality has been similar regardless of 
whether the FOT (Clément et al 1983, Solymar et al 1984) or the IOS method has been 
applied (Bisgaard & Klug 1995, Klug & Bisgaard 1996). Despite the concordant results in 
asthma, the concordance between FEV1 and Raw in cystic fibrosis has been reported to be poor 
(Lebecque & Stănescu 1997). This may be due to the effect of dynamic compression of the 
airways during forced expiratory manoeuvres, which is lacking when Raw is measured at tidal 
breathing. In the present study, a significant but low concordance between Rrs5 and FEV1 
was found. However, the concordance was better in Xrs, which delineated the severely 
affected children (BPD) more accurately than Rrs. (I) This is in agreement with the previous 
findings on asthmatic children, where Xrs has been shown to correlate well with FEV1 and 
Raw during challenge tests (Solymar et al 1984, Bisgaard & Klug 1995, Klug & Bisgaard 
1996, Bouaziz et al 1996). Compared to an increase in Rrs, a decrease in Xrs has been 
reported to be a more sensitive (Buhr et al 1990, Bisgaard & Klug 1995, Klug & Bisgaard 
1996) and specific (Bouaziz et al 1996) indicator of thoracic obstruction. 
Theoretically, Xrs is mainly determined by the elastic and mass-inertial properties of the 
respiratory system; at low frequencies the former predominate and Xrs varies in relation to 
dynamic compliance (Solymar et al 1989). The dynamic compliance of the lung is impaired 
in both peripheral airway obstruction and disorders causing stiffness of the lungs, such as 
interstitial fibrosis, both changes likely to be present in BPD. As in our study, no significant 
relationship was found between Xrs and DLCO, the decreased Xrs values are more likely to be 
due to airway obstruction than interstitial fibrosis. Rrs5 was closely associated in Raw in body 
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plethysmography. At the lower rate of resistance, IOS showed higher values than Raw, since 
the method measures total respiratory resistance. At high values, Rrs5 underestimates 
resistance (Cauberghs & Van de Woestijne 1989), as in our study. 
The data on the range of normality in the bronchodilator response elicited with oscillatory 
methods are still sparse (Delacourt et al 2000). In our study, the bronchodilator response in 
Xrs5 correlated significantly with ∆FEV1, which was in line with the concordance found 
between Xrs5 and FEV1.  
 
To conclude, being easy to perform, IOS measurement alone may produce important 
information on the lung function of preschool or school-aged children with neurological 
handicap or other disabilities impairing cooperation. The bronchodilator test might be 
valuable in examining children unable to produce forced expiration, and it should be further 
evaluated. In combination with conventional lung function tests, IOS yields both concordant 
and also additive information, as it assesses the quiet tidal breathing instead of forced 
expiration. We chose to use the IOS method in our studies of long-term sequelae after the 
administration of perinatal DEX (III and IV). 
 
3.  Exhaled nitric oxide 
  
In eNO measurement, to avoid nasal NO contamination (Alving et al 1993), we used a 
technique of single exhalation through a mouthpiece against a resistance, creating a back 
pressure to close the soft palate (Kharitonov et al 1997). The present guidelines do not 
recommend the use of a nose clip, but allow it in cases when the subject cannot avoid nasal 
inspiration or nasal exhalation (ATS 1999). We used it systematically, as this technique of 
breathing was familiar to the children from previous tests. Because neurological disabilities 
and small lung volumes affect cooperation, the children were individually supported in the 
performance. This technique was considered reliable in all study children, including the 
youngest control child, who was 5.3 years old. The eNO concentration is highly flow-
dependent (Silkoff et al 1997). The expiratory target flows recommended at that time by the 
ERS appeared unsuitable for us, as they require large lung volumes. Therefore, we used lower 
target flows, which were still higher than those subsequently recommended by the ATS 
(1999). Some variation of flows had to be accepted because of limited cooperation. Despite 
this variation, we achieved recordings with acceptable individual variation in eNO, and the 
flows in the different groups did not differ significantly. Even though relatively high flows 
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may mask some differences, they did not mask the differences between the atopic and non-
atopic groups. 
 
In our prematurely born children, the atopic children presented with higher eNO values than 
the non-atopic ones, in line with the previous findings (Frank et al 1998, Franklin et al 1999, 
Mattes et al 1999, Piacentini et al 1999). Therefore, we excluded the atopic children and those 
on regular glucocorticoid inhalations, known to suppress eNO, from the main study of eNO in 
BPD. Living with a smoker (45%) had no detectable impact on eNO values either, in 
agreement with previous findings (Franklin et al 1999). Despite the evident presence of 
significant obstructive and restrictive lung function abnormalities in the study children, 
especially those with BPD, we found no significant differences in eNO concentrations and 
output between the non-atopic BPD, non-BPD and full-term control children. (II) 
 
While prior studies on the inflammatory characteristics of BPD focused on the early neonatal 
period (Merritt et al 1981, Speer 1999), postnatal follow-up data are scanty. Airway 
inflammation has been assessed by eNO measurements in adult asthmatics (Alving et al 1993, 
Kharitonov et al 1994, Persson et al 1994), in exacerbations of COPD (Maziak et al 1998) 
and in asthmatic children (Lundberg et al 1996, Baraldi et al 1997, Nelson et al 1997), 
particularly ones with atopy (Frank et al 1998). In asthmatic children, eNO concentration and 
sputum eosinophil counts were found to be concordant, and eNO was proposed as an easy-to-
perform marker of eosinophilic airway inflammation (Mattes et al 1999, Piacentini et al 
1999). In a recent study, eNO was superior to baseline lung function and bronchial 
responsiveness in identifying preschool children with asthma (Malmberg et al 2003). 
However, the role in non-atopic asthma was still unclear. In ventilated preterm infants, the 
persistence of high bronchoalveolar lavage fluid nitrate associated with the development of 
BPD (Vyas et al 1999), and high eNO levels shortly after birth were found in some infants 
developing BPD (Aikio et al 2002). Exhaled NO concentrations decreased after DEX 
treatment (Williams et al 2004). In face mask measurements at term, high eNO levels were 
related to the presence of BPD (Leipälä et al 2004). No previous reports of eNO values in 
children born very preterm with BPD exist. 
As high eNO in atopic asthma is likely to represent airway inflammation, the lack of eNO 
elevation in the school children with BPD in our study is evidence against airway 
inflammation. However, high inducible NOS activity in the airway inflammatory cells or high 
eNO is not a constant finding in neonatal inflammatory lung disease (Aikio et al 2000, Aikio 
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et al 2003). Non-atopic children born very prematurely showed no evidence of increased 
concentrations of eNO. Nor did the eNO levels correlate with the severity of lung disease, as 
determined by conventional lung function studies. As our study children with most severe 
lung disease were all non-atopic, the eNO measurement did not serve in assessing the degree 
of lung disease in a stable phase in these children. 
 
To conclude, in non-atopic children born very prematurely, exhaled NO values did not 
correlate with impaired lung function, indicating that eNO was not an inflammatory marker in 
established BPD. However, because asthma is a common disease, eNO measurements may be 
beneficial in the differential diagnosis of symptomatic children with chronic lung disease of 
prematurity and atopic asthma. 
 
4.  Growth 
 
In our study, the prematurely born children had significantly lower standardized height than 
the controls, but the difference was seen only in boys. This confirms the findings of Hack et 
al (2003), who showed that boys were shorter and lighter at the age of eight years, followed 
by poorer catch-up growth until 20 years, and that this trend was especially obvious in those 
who were SGA. Weight adjusted for height in our study did not differ between the groups. 
Our BPD children weighed less adjusted for height than the non-BPD children, but in contrast 
to earlier findings (Northway et al 1990b, Hakulinen et al 1996, Pelkonen et al 1997), they 
were not shorter for age. 
In previous studies, BPD children born during 1970-1980´s commonly showed growth 
retardation in infancy (Northway 1979, Markestad & Fitzhardinge 1981), at school age 
(Hakulinen et al 1996, Pelkonen et al 1997) or in adolescence (Northway et al 1990b), while 
some others found no impairment (Bader et al 1987). Growth impairment was also seen in 
VLBW children at preschool or school age or in adolescence, with or without catch-up 
growth (Niklasson et al 2003, Hack et al 2003, Korhonen et al 2004c), and in ELBW children 
(Doyle 2000a), but this findind has not been confirmed by others (Kilbride et al 2003). 
 
Postnatal DEX may impair growth during treatment, but this effect is usually reversible 
(Jones et al 1995, O´Shea et al 1999). Our study did not reveal any significant differences in 
growth between the postnatal DEX and placebo groups, but the latter were shorter for age 
than the controls. Among boys, the difference persisted. The cumulative dose of postnatal 
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DEX during the first year of life did not correlate with the growth parameters, either (III and 
IV). Thus, postnatal DEX was not shown to have a negative effect on somatic growth at 
school age, in line with the previous findings at 2-3 years (Jones et al 1995, Romagnoli et al 
2002). (III) 
A single dose of antenatal DEX had no harmful effect on the growth parameters in our 
study, as reported in the follow-ups of randomized glucocorticoid trials at 3-20 years of age 
(MacArthur et al 1982, CGAST 1984, Smolders-de Haas et al 1990, Dessens et al 2000). 
After antenatal DEX, body height and weight were slightly greater at three years (CGAST 
1984), and after betamethasone, girls were taller and heavier at six years (MacArthur et al 
1982) than after placebo treatment. In our study, the placebo group was shorter for age than 
the controls. (IV) 
 
Our DEX studies suggest that the diseases associated with prematurity itself rather than 
glucocorticoid caused the growth retardation. 
 
5.  Atopy 
 
One fourth of the study children were atopic, i.e. had positive skin prick tests. In Study II, 
atopy was less common in the children with BPD (8%) than in those without BPD (33%). The 
atopic children had a higher birth weight and needed less initial respiratory care than the non-
atopic study children. Of the children with severe initial respiratory disease in Study III, only 
one was atopic, in contrast to 35% of the Study IV participants, even though the rates reported 
for familial atopy did not differ. None of the skin prick-positive children had received 
postnatal DEX, which differed significantly from the skin prick-negative children. 
In a Finnish population-based study, positive skin prick tests were found in 77% of 
schoolchildren with asthma or other symptoms from lower airways and in 40% of controls 
with no chronic or recurrent respiratory symptoms (Remes & Korppi 1996). 
 
Our results support the proposal that severe neonatal lung disease is not associated with an 
increased incidence of atopy (Pelkonen et al 1997). Thus, we propose that the initial 
inflammation and inflammatory response, the medications used or the strategies to support 
preterm infants may modify the direction of the inflammatory sequence towards skin prick 
negativity. 
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6.  Respiratory symptoms and medication  
 
Half of our study children had glucocorticoid inhalations at 12 or 24 months of age, half 
reported prolonged respiratory symptoms, and 10% reported regular use of inhalations. In the  
Finnish study of schoolchildren, 7% had asthma and 8% other symptoms from lower airways 
at the age of 7-12 years (Remes & Korppi 1996). The excess of morbidity and medication in 
our study is in line with the previous studies of preschool or school-aged children born 
preterm during the same period (Pelkonen et al 1997, Gross et al 1998, Korhonen et al 
1999a). The abundant use of glucocorticoid inhalation by the BPD children at 12 months 
might partly reflect, besides their high respiratory morbidity, the strategies to treat and follow 
up BPD at that time; the use at 24 months probably reflects more accurately the prevailing 
respiratory morbidity. The frequency of reported symptoms did not associate with BPD, as in 
other studies (Gross et al 1998, Korhonen et al 1999a), but had a negative association with age 
at the time of the study. The use of inhaled glucocorticoid was (Korhonen et al 1999a) and β2-
sympathomimetic agents (Gross et al 1998, Korhonen et al 1999a) tended to be more common 
in BPD children. The use of inhaled medication during the preceding year associated with 
impaired lung function, and no extra use due to the diagnosis of BPD was suspected at school 
age. 27% of our study children had neither had prolonged respiratory symptoms nor used 
inhalations until the time of study. 
 
Reports of respiratory symptoms during follow-up after postnatal DEX trials are few: Jones et 
al (1995) found no difference at three years, Yeh et al (1998) reported less upper respiratory 
infections and rehospitalization at two years, and O´Shea et al (1999) found less frequent 
rehospitalizations by the age of one year in the DEX than in the placebo group. Our finding of 
no association between a moderately early course of postnatal DEX or the length of DEX 
therapy during the first year of life and respiratory morbidity and medication are in line with 
these previous findings in younger children. One fourth in each group had neither had 
prolonged symptoms nor used inhalations by their enrolment in the study. (III) 
The follow-up studies of randomized trials infrequently assess respiratory morbidity after 
antenatal glucocorticoids: Smolders-de Haas et al (1990) reported more hospital admissions 
because of infections or respiratory diseases during the first year after betamethasone 
treatment. In our study, the use of antenatal DEX did not associate with respiratory morbidity 
or medication at school age. (IV) 
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In all, half of our study children with and also without BPD reported prolonged respiratory 
symptoms during the preceding year, suggesting that preterm infants even without a high 
risk for respiratory morbidity may need a careful follow-up. 
   
7.  Smoking in the family 
 
Exposure to tobacco smoke was common in our study children, as shown in the children born 
very prematurely, but did not differ between the BPD and non-BPD groups or between the 
subgroups in the DEX studies.   
In contrast to previous findings (Chan et al 1989a), maternal smoking or smoking during 
pregnancy had no detectable association with respiratory symptoms. Maternal smoking or 
smoking during pregnancy was not associated with impairment of basic lung function, as 
assessed by spirometry and IOS. Nor did smoking during pregnancy correlate with the values 
of diffusing capacity tests. In the antenatal DEX study, however, the preterm children with 
smoking mothers had significantly lower DLCO values and a tendency towards lower KCO 
values compared with the children of non-smoking mothers. Smoking in the family also 
tended to associate with decreased diffusion capacity. (IV) 
 
Our study suggests that daily exposure to tobacco smoke might present a major threat to the 
already impaired lung function of children born very preterm. Therefore, it is of utmost 
importance to prevent children born very prematurely from starting smoking themselves, as 
already emphasized by Northway et al (1990b) and more recently by Doyle et al (2003). 
 
8.  Lung function  
 
Prematurely born children with or without BPD 
Our study children had significantly impaired basic lung function in spirometry, comparable 
to the previous studies of children born nearly ten years earlier (Hakulinen et al 1996, 
Pelkonen et al 1997). The response to bronchodilator was increased, in line with the previous 
findings of increased bronchial responsiveness and lability in home monitoring of PEF 
(Pelkonen et al 1997). The values of basic spirometry were strikingly more seriously impaired 
in BPD than in non-BPD children, similarly to the other studies using the criterion of oxygen 
at 36 weeks (Pelkonen et al 1997, Gross et al 1998, Jacob et al 1998, Kilbride et al 2003), but 
see Hakulinen et al (1996). (I)  
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combination of antenatal and postnatal glucocorticoids or their repetitive use may further 
increase the hazards. On the other hand, low dosage may decrease side effects. The possible 
beneficial and adverse long-term effects on lung growth remain to be studied further. 
 
Lung function after postnatal dexamethasone treatment 
Few follow-up studies of postnatal DEX trials are available (Jones et al 1995, Yeh et al 1998, 
O´Shea et al 1999, Shinwell et al 2000), with no results of long-term lung function. In both 
groups of the present study, mechanically ventilated infants showed signs of airway 
obstruction and increased bronchodilator responsiveness at school age in spirometry and, 
correspondingly, in IOS. The only significant difference between the randomized groups was 
the lower FVC in the placebo group. Half of the children in the placebo group failed to 
perform the diffusing capacity test, rendering their results invalid. 
Thus, we did not find any negative effects of our moderately early postnatal DEX 
treatment on pulmonary outcome. The common use of later DEX treatment in the placebo 
group (50%) may bias the results. (III) 
 
Lung function after antenatal glucocorticoids  
Follow-up studies of lung function after randomized antenatal trials continued until school 
age are scarce: no negative effects of glucocorticoid on lung function were found at 10-12 
years after betamethasone (Smolders-de Haas et al 1990) or at six years after DEX treatment 
(Wiebicke et al 1988). In the latter case, however, only 12% of the original participants were 
studied. In a cohort study, no significant differences were seen in lung function between the 
betamethasone and control groups at the age of 14 years (Doyle et al 2000b). 
In the present study, both groups of children born very prematurely showed signs of 
airway obstruction and increased bronchodilator responsiveness in flow-volume spirometry 
compared with the controls. Increased resistance and lower reactance in IOS in VLBW 
children indicated airway obstruction. The study groups had lower diffusing capacity than the 
controls. The only significant difference in lung function tests between our DEX and placebo 
groups was the higher bronchodilator responsiveness (∆FEV1) in the placebo group. Although 
the lower mean reactance, which mainly reflects respiratory dynamic compliance, and KCO 
would seem to suggest more pronounced parenchymal involvement in the placebo group than 
in the DEX group, the size of the placebo group was too small to warrant definite conclusions. 
In line with previous studies, our data imply that antenatal DEX treatment has no negative 
effects on pulmonary outcome. (IV) 
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9.  Cardiovascular findings 
 
In our study, only one girl with severe BPD had cardiac hypertrophy and increased pulmonary 
arterial pressure still at school age (III and IV). This confirms the previous findings of no 
cardiac hypertrophy (Farstad et al 1995, Korhonen et al 2004b) or significant pulmonary 
hypertension at 2-7 years of age (Korhonen et al 2004b) in children born in the late 1980´s or 
early 1990´s, contrary to the frequent finding of right ventricular hypertrophy and 
cardiomegaly with cor pulmonale that accompanied the severe old BPD (Northway et al 
1967, Markestad & Fitzhardinge 1981, Smyth et al 1981, Northway 1990a). 
Abnormal lung vascular growth may be important in disturbing alveolar septation and the 
formation of lung alveoli (Burri & Hislop 1998, Jobe & Bancalari 2001, Abman 2001, Parker 
& Abman 2003). Glucocorticoids regulate lung and vascular growth and maturation at 
different levels. Pharmacological doses may impair alveolarization by suppressing the 
proliferation of capillaries within the septa (Tschanz et al 1995, Burri & Hislop 1998, 
Tschanz et al 2003). However, this process may be reversible and depend on the length and 
dosage of glucocorticoid therapy. As there are large interspecies differences in the duration of 
vascular growth and the structural maturation of the lung, the interpretation of the 
experimental results remains uncertain. (Burri & Hislop 1998, Tschanz et al 2003) 
Pulmonary hypertension with raised pulmonary vascular resistance has been demonstrated 
by cardiac catheterization in children with severe BPD until five years of age, associated with 
poor prognosis, especially in those not responding to oxygen (Abman et al 1985, Berman et al 
1986, Bush et al 1990). The neonatal decrease in pulmonary arterial pressure, assessed non-
invasively by echocardiography, is delayed in infants with RDS and may remain persistently 
elevated in infants who subsequently develop BPD and serve as a sensitive marker of lung 
injury (Gill & Weindling 1993, Subhedar et al 1998); it was still elevated at the age of one 
year in BPD children (Subhedar & Shaw 2000). Pulmonary vasodilators, particularly inhaled 
NO, may decrease the risk of BPD by decreasing intrapulmonary and extrapulmonary 
shunting (Jobe & Bancalari 2001) and promoting lung growth and alveolarization by serving 
as a downstream agonist of VEGF (Tang et al 2004). 
Thus, the cardiac findings following BPD are modified in accordance with the changing 
disease and treatments. 
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Cardiological findings after postnatal dexamethasone treatment 
In our study of survivors, no hypertrophic cardiomyopathy was found (III).  
After postnatal DEX treatment, hypertension was frequent (CDTG 1991, Ng 1993) 
contributing to the development of myocardial hypertrophy or cardiomyopathy (Werner et al 
1992, Ng 1993, Evans 1994, Yeh et al 1997), and fatal cardiomyopathy was reported (Riede 
et al 2001). However, in randomized trials (Kothadia et al 1999, Romagnoli et al 1999), 
DEX-associated ventricular septal hypertrophy and left ventricular outflow obstruction were 
usually reversible, although some infants presented with clinical symptoms (Bensky et al 
1996, Zecca et al 2001).  
The fall in PAP seen after DEX treatment did not correlate with the respiratory 
improvement. This did not support the theory of a DEX effect mediated through a reduction 
in pulmonary vascular resistance. (Evans 1994) We found no differences in the Doppler-
mode-derived variables between the DEX and placebo groups. Two patients in the DEX 
group tended to have a short pulmonary artery acceleration time, but with no evidence of 
elevated PAP, in contrast to a previous study showing short acceleration times (<100 ms) to 
be associated with increased pulmonary vascular resistance (Farstad et al 1995). In the DEX 
group, three patients had a tricuspid regurgitation gradient of 30-40 mmHg, with no clinical or 
X-ray findings of pulmonary hypertension. Clinical and echocardiographic manifestations of 
cor pulmonale were evident in one placebo group girl with BPD. Our DEX and placebo 
groups did not differ in PAP measured non-invasively. Mild tricuspid regurgitation was found 
in three asymptomatic patients. One girl in the placebo group had ASD secundum with a 
remarkable left-to-right shunt of 2.0. She had no BPD, but chest X-ray revealed an enlarged 
heart and minor congestion in the lungs without evidence of chronic pulmonary changes. The 
ASD was successfully closed with a device at the age of nine years. (III) However, in early 
infancy, ASD may be a risk factor for BPD (Motz et al 2000). 
    
Cardiological findings after antenatal glucocorticoids 
In the present study, a trend towards less PDA after DEX treatment (33%) than after placebo 
(100%) was seen, as suggested previously (Eronen et al 1993), with no significance in 
difference (IV). 
In randomized trials comparing fetal effects, both betamethasone and DEX induced 
significant but reversible changes in heart rate acceleration and variability (Mulder et al 1997, 
Rotmensch et al 1999, Subtil et al 2003). No constant effect has been confirmed on PDA 
(Crowley 1995, Wright et al 1995). Antenatal DEX did not appear to affect cardiac  
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dimensions and blood flow velocity in neonatal preterm infants (Skelton et al 1998).  
In a follow-up of randomized trials, more abnormalities, mostly heart murmur, were 
reported at three years in the placebo group (CGAST 1984). Systolic blood pressure was 
significantly lower in the betamethasone group, but no difference was seen at 20 years 
(Dessens et al 2000). No echocardiographic studies exist on the long-term effects of antenatal 
glucocorticoid on heart function or growth. In the present study, the cardiac outcome did not 
differ significantly at school age, regardless of whether antenatal DEX or placebo was 
administered. None of the infants required cardiovascular treatment. (IV) 
 
To conclude, antenatal or postnatal DEX treatment was not associated with abnormal cardiac 
function or growth. Nor was BPD frequently accompanied by cardiac findings. However, 
cardiac evaluation is important in symptomatic children after DEX treatment, as some 
individuals may be liable to serious side-effects, and in preterm born children with severe 
lung disease, as the lung disease may lead to cardiac sequelae or mask the cardiac symptoms. 
 
10.  Neurosensory development 
 
Before the era of antenatal glucocorticoid and surfactant in the 1970-1980´s, the live birth 
prevalence of CP, especially spastic diplegia, increased in a population-based Swedish 
follow-up, reflecting the improved survival of VLBW infants (Hagberg et al 1989). Later, no 
further increase was seen, but there was a slight decrease in preterm CP. In 1991-1994, the 
prevalence was 82 per 1000 for infants of 1000-1499 g birth weight (Hagberg et al 2001). 
IVH and PVL were powerful predictors of CP (Hagberg et al 1996, Salokorpi et al 1999). The 
neurosensory development of ELBW infants was recently reviewed by Tommiska (2003). 
Previously, VLBW infants born in the 1970´s, especially those with BPD, were shown to 
have more neurological abnormality than term controls at the age of 10-12 years (Vohr et al 
1991).    
 
Neurosensory development after glucocorticoid treatment 
Glucocorticoids impair the growth and development of the immature brain, but they may 
either enhance or reduce brain injury after hypoxia, depending on dosage or timing. 
(Whitelaw & Thoresen 2000) After widespread use of postnatal DEX and initial reports of 
adverse neurodevelopment in follow-up, concern also arose about the possible long-term 
adverse effects of antenatal glucocorticoid, especially when used repetitively (Ng 1993). 
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Antenatal glucocorticoid treatment has been considered a physiological glucocorticoid 
stress for the fetus, comparable to other maternal environmental stress factors. During a 
sensitive time window, it may program the cardiopulmonary system, brain and other organs 
for postnatal life. The effect may be modified by the immediate postnatal environment. 
Apparently, similar events early in life may produce different responses, depending on their 
intensity and timing. (Matthews 2000, Seckl 2001) Thus, by improving neonatal adaptation, 
antenatal glucocorticoid treatment may improve the outcome. 
    
Neurosensory development after postnatal dexamethasone treatment 
After delayed DEX treatment, new periventricular abnormalities on brain ultrasound scans 
were reported (Noble-Jamieson et al 1989). The following studies of moderately early and 
early treatment did not reveal any significant effects on the incidence of severe IVH or 
severe ROP (Halliday & Ehrenkranz 2000ab), but did reveal slower head growth during DEX 
treatment in 2-week and 4-week groups (Papile et al 1998). One early trial was terminated 
owing to the adverse outcome, particularly PVL, in the DEX group (Soll et al 1999, Vermont 
Oxford Study 2001), but one study found more IVH of any grade in the placebo group 
(Garland et al 1999). Head circumference was smaller at 36 gestational weeks in the DEX 
group in a recent study of early low-dose treatment (Stark et al 2001). 
In our study of moderately early DEX treatment, no differences emerged between the 
groups in abnormal ultrasound findings; one girl in the DEX had IVH grade 3-4 and one boy 
in the placebo group IVH grade 2-3, both diagnosed before study entry. In each group, one 
child received cryotherapy for ROP. (III)     
 
Few follow-up results of DEX trials are available. At first, the small trial of a 42-day 
moderately early course showed improved neurodevelopmental outcome at 15 months of 
age (Cummings et al 1989). Thereafter, in the 209 VLBW children of the CDTG trial (1991) 
born before the era of antenatal glucocorticoid and surfactant, no difference was evident at 
three years after delayed treatment in CP (DEX vs placebo, 20% vs 17%), severe disability, 
severe or moderate disability, visual or hearing loss or expected need for special school or 
extra help at school (Jones et al 1995). Later, a 42-day delayed course in surfactant-treated 
infants (Kothadia et al 1999) increased the risk of CP (25% vs 7%) (O´Shea et al 1999). 
Similarly, in two early trials, a 4-week course (Yeh et al 1997) increased neurological 
abnormality at two years (40% vs 17%) (Yeh et al 1998), and a 3-day course in surfactant-
treated infants (Shinwell et al 1996) increased the incidence of CP (49% vs 15%) and 
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developmental delay at 2-6 years of age (55% vs 29%) (Shinwell et al 2000). In the latter 
trial, the DEX-treated infants tended to have more PVL and less IVH than the placebo-treated 
ones, with no significant difference; all infants with PVL, 38% of those with IVH grade 1-2 
and 53% of those with IVH grade 3-4 developed CP. In these early studies, the children 
were more mature at birth than ours.  In a recent follow-up of an early trial, the 4-week course 
associated with smaller head circumference, poorer motor skills, lower IQ and more 
significant disabilities at eight years of age (Yeh et al 2004). 
Five (31%) of our preterm study children had CP (DEX 38%, placebo 25%) and 13% 
were severely and 44% severely or moderately disabled (DEX 38%, placebo 50%), one with 
visual loss. All the children were able to walk without support, and 88% attended normal 
school. All could perform at least some lung function tests. The hospital record data of the 
four children lost from this follow-up did not change the results: no CP was found, all could 
walk without support, all attended normal school, and one in each group had learning 
difficulties. Our findings of CP and disability are in line with those of Jones et al (1995). 
Thus, severe or moderate disability was common, as were minor neurological impairment and 
learning disabilities. We found no significant association between postnatal DEX treatment 
and neurological outcome at school age. 
In the recent trials, DEX was used less often in the placebo group than earlier (Yeh et al 
11%, O´Shea et al 0%, Shinwell et al 33%, our study 50%, Jones et al 40%), and the use of 
antenatal glucocorticoid was more common (Yeh et al 32%, O´Shea et al 32%, Shinwell et al 
26%, our study 25%, Jones et al 0%). In a review by Barrington (2001), the studies with less 
than 30% contamination with open-label DEX showed a greater steroid effect and a high risk 
of CP associated with postnatal DEX. As half of our placebo children received open-label 
DEX, the long-term safety of DEX cannot be suggested based on the similar outcomes 
between the DEX and placebo groups. 
 
After the documented effects of DEX on developing brain, based on early and some 
delayed trials, the American Academy of Pediatrics and the Canadian Paediatric Society 
(2002) published guidelines for postnatal glucocorticoid treatment: the use was to be limited 
to exceptional clinical circumstances. However, glucocorticoids continue to be used 
frequently in the USA and Europe (Soll 2003, Truffert et al 2003), especially in ELBW 
infants (Barrington 2001). The excess of adverse neurological outcomes after early DEX 
treatment may be explained by the instability of the infant in the first few days after birth, 
when its tolerance of adverse events may be low, and the risk of cerebral ischemia may be 
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increased. According to currently available evidence, neurodevelopmental risks supervene the 
benefits to lung function. The cost-benefit ratio of DEX treatment may possibly shift from 
negative to positive when treatment is started after the age of 7-10 days. (Halliday 2003) This 
assumption is supported by the present results. This is constant dilemma in neonatological 
practise. Antenatal glucocorticoids, especially repeated courses, may influence the effect of 
DEX and complicate the conclusions of long-term sequelae. Further research is needed to 
assess the dosage and duration of DEX or other glucocorticoid in the treatment of VLBW 
infants predisposed to various antenatal insults, infections, mechanical ventilation and 
postnatal interventions. 
 
Neurosensory development after antenatal glucocorticoids 
Antenatal glucocorticoids prevent IVH (Crowley 1995, NIH 1995, Wright et al 1995). 
However, in a retrospective study of 883 preterm infants, antenatal DEX, but not 
betamethasone, predisposed infants to cystic PVL (Baud et al 1999), while others found no 
increase in abnormal brain ultrasound findings, including PVL, after DEX in ELBW infants 
(LeFlore et al 2002). Contrary to this, our study showed abnormal brain ultrasound findings to 
be less common in the DEX group than in the placebo group. In a prospective cohort study, 
repeated doses of glucocorticoids associated with a decrease in head circumference at birth, 
representing a reduction in cranial volume of nearly 11% (French et al 1999). Recently, 
betamethasone was preferred to DEX, and no more than two courses were recommended 
(Baud 2004). 
 
Few long-term follow-up results of randomized antenatal trials continued until school age or 
adulthood are available. In a Dutch study of 81 adults at 20 years of age, no significant 
differences were found in CP or cognitive function between the betamethasone and placebo 
groups (Dessens et al 2000); these adults had been more mature at birth than our children, 
ranging from 27 to 40 gestational weeks. Previous follow-up studies after antenatal 
betamethasone (MacArthur et al 1982) and DEX trials (CGAST 1984) revealed no negative 
neurological outcomes at six years (MacArthur et al 1982) or three years (CGAST 1984) of 
age: 82% and 55% of the survivors were studied, respectively. A cohort study showed 
teenagers exposed to antenatal betamethasone to have better cognitive functioning at 14 years 
compared with VLBW controls (Doyle et al 2000b).  
In our study, seven (20%) children had CP (DEX 11%, placebo 50%), 6% needed a 
wheelchair or a walking aid, 9% had visual loss, and 6% needed a hearing aid. 17% were 
   
 97
severely and 34% severely or moderately disabled (DEX 22%, placebo 75%). Minor 
neurological impairment and learning problems were common in both groups. 89% of the 
children in the DEX group and 38% in the placebo group attended normal school; speech 
therapy, physiotherapy or extra help at school was frequently needed. In the DEX group, the 
normal school attendance rate was higher, and there were less severe to moderate disability 
and a tendency to less CP than in the placebo group, in line with the previous findings of no 
negative outcome at school age after antenatal betamethasone (MacArthur et al 1982, Dessens 
et al 2000). In contrast to previous studies, we presented the data of non-participants, i.e. 98% 
of the survivors of the original trial, with no change in the results. (IV) 
 
Thus, in our study, antenatal DEX associated with better neurological outcome at school age.
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CONCLUSIONS 
 
1.  Obstructive and restrictive pulmonary dysfunction, bronchial hyperreactivity 
and decreased gas exchange were evident in children born very prematurely, 
especially in those with BPD. The impulse oscillometric method yielded lung 
function information concordant with conventional methods. Being easier to 
perform than spirometry, IOS served well in studying school-aged children, even 
ones with neurological handicap or severe lung disease, and it may be useful in 
preschool children as well.   
 
2.  Children with BPD rarely suffered from atopy. In non-atopic children born 
very prematurely, exhaled nitric oxide values did not correlate with impaired lung 
function, indicating that eNO was not an inflammatory marker in established BPD. 
However, since atopy associated with increased eNO levels, we suggest that eNO 
measurements may be valuable when studying atopic asthma even in preterm 
children. 
 
3. Neonatal dexamethasone therapy beginning ten days after birth in severely ill 
ventilator-dependent infants associated with no detectable adverse effect on 
cardiopulmonary function, somatic growth or neurosensory development at school 
age. Severe or moderate disability was common. As half of the placebo children 
received DEX after the trial, long-term safety cannot be suggested. More research is 
needed for future conclusions.  
 
4.  Antenatal DEX treatment was not associated with any detectable adverse effect 
on cardiopulmonary function or somatic growth. Besides initially helping more 
infants to survive, it also caused a tendency for the children to have an improved 
neurological outcome, as they had a higher rate of normal school attendance and 
less severe or moderate disability. Survival without CP increased. In future studies 
of different treatment strategies, the golden standard will be antenatal 
betamethasone rather than placebo.  
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5.  Children born very prematurely have an increased risk of abnormal lung 
function and frequent respiratory symptoms at school age. Even though those with 
the most severe initial lung disease were non-atopic, some children may 
additionally develop atopic asthma. With immature survivors and differences in the 
etiology of preterm birth, the clinical course of chronic lung disease may be 
modified. We propose that lung function studies are important in the follow-up of 
children born very preterm or with VLBW, with or without BPD. Asthma 
medication should be tried if the clinical picture is reminiscent of asthma. Early 
exposure to tobacco smoke associated with impaired gas exchange. These and other 
very high-risk children should be strongly advised against smoking. 
 
6.  Antenatal or postnatal DEX treatment was not associated with abnormal 
cardiac function or growth. We propose that cardiac evaluation should be included 
in the follow-up of preterm children with severe lung disease, as the lung disease 
may lead to cardiac sequelae or mask the symptoms of a cardiac defect. 
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